FIELD OF THE INVENTION

The present invention relates to methods of modulating the alkaloid content a plant or part thereof or cell or cell culture. The invention also extends to methods of modulating the expression and/or activity of polypeptides which modulate alkaloid content within plants. Alternatively, the invention provides methods of modulating the expression and/or activity of genes which encode polypeptides which modulate alkaloid content within plants. The invention also extends to constructs, which can be used to modulate the polypeptides. The invention further relates to plant cells and plants modified to achieve a modulation in alkaloid content. The invention also relates to a processed and harvested leaf from such modulated plants and use thereof in a tobacco industry product, including combustible smoking articles.

BACKGROUND

Alkaloids are a group of naturally occurring compounds which mostly contain basic nitrogen atoms and are produced by a large variety of organisms including bacteria, fungi, plants and animals.

Alkaloids may be classified according to the similarity of the carbon skeleton e.g. indole-, isoquinoline- and pyridine-like. Pyridine derivatives are one class of monomeric alkaloids; this class includes simple derivatives of pyridine, polycyclic condensed and noncondensing pyridine derivatives and sesquiterpene pyridine derivatives. Examples are nicotine, nornicotine, pseudooxynicotine, anabasine, myosmine and anatabine.

Most of the known biological functions of alkaloids are related to protection. Neuroactive molecules, such as caffeine, cocaine, morphine, and nicotine, act as defence compounds against invading predators. The accumulation of these alkaloids is the result of signal transduction cascades that monitor gene expression, enzyme activities, and alkaloid concentrations. The fine-tuning of alkaloid content in the plant involves negative feedback loops and degradative pathways.

Nicotine occurs naturally in several varieties of plants but is found at the highest level in the tobacco plant. Cultivated tobacco produces 2-4% alkaloids of total dry weight. Nicotine is produced in wild and cultivated Nicotiana species and plays an important role in plant defence against herbivores and insects (Voelckel et al. (2001) Oecologia 127(2): 274-280, incorporated herein by reference). It accounts for -90% of the total alkaloid content. The remaining 10% of the alkaloid pool is mostly constituted by the structurally related compounds nornicotine, anatabine, anabasine and pseudooxynicotine (PON).

The regulation of alkaloid content in tobacco is complex. Several factors including genotype, environment, fertilization and agronomic practices (e.g. topping) affect alkaloid levels in tobacco plants. Some key regulators of nicotine biosynthesis are well characterized, for example putrescine N-methyltransferase (PMT), which plays a pivotal role in this pathway, is activated by members of the ethylene responsive factor (ERF) superfamily, the largest transcription factor family in the tobacco genome (Rushton et al. (2008) Plant Physiol. 147(1): 280-295 incorporated herein by reference). Other transcription factors that induce alkaloid biosynthesis belong to the MYC2-like basic helix-loop-helix (bHLH) family. MYC2-like bHLHs regulate alkaloid levels directly, through the Gbox-mediated binding and activation of alkaloid structural genes, and indirectly, through the activation of ERFs.

Tobacco pyridine alkaloids are precursors of tobacco-specific nitrosamines (TSNAs) that form during the post-harvest leaf curing. The four primary TSNAs found in cured tobacco leaves are N’-nitrosonornicotine (NNN), N’nitrosoanatabine (NAT), N’-nitrosoanabasine (NAB) and 4- (methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). During the post-harvest leaf curing, reactions between pyridine alkaloids and nitrosating species leads to the formation of tobacco- specific nitrosamines (TSNAs). PON is likely to function as the direct precursor in the synthesis of the TSNA NNK (Bush et al., 2001 incorporated herein by reference). Reducing the production and accumulation of TSNAs is of high importance. The CYP82E family of nicotine demethylase genes is one of the primary regulators of nicotine to nornicotine conversion, and altering their activity or accumulation may result in a decrease in NNN levels. However, no enzymes or genes responsible for producing PON have been identified thus far.

As described in the Examples, the inventors sought to investigate genes responsible for alkaloid and/or TSNA precursor synthesis, with the aim of modulating alkaloid content in plants, e.g. decreasing TSNA content in tobacco.

SUMMARY OF THE INVENTION

It has been surprisingly found that by modulating the activity or expression of a gene encoding an RNA binding protein the alkaloid content and/or TSNA content or precursor of TSNA content of plants can be modulated. The gene(s) as taught herein which encode RNA binding proteins, for example Nitab4.5_0013685g0010.2, are regulators of alkaloid and TSNA precursor content in cultivated tobacco. In particular the gene(s) as taught herein, for example

Nitab4.5_0013685g0010.2, is a regulator of alkaloid content in cultivated tobacco. Nitab4.5_0013685g0010.2. encodes an RNA binding protein according to the present invention. Nitab4.5_0000308g0150.2, Nitab4.5_0003919g0010.2, Nitab4.5_0002978g0020.2,

Nitab4.5_0001361g0220.2, Nitab4.5_0002978g0030.2, Nitab4.5_0001361g0225.2,

Nitab4.5_0003978g0020.2, Nitab4.5_0000078g0240.2, Nitab4.5_0005079g0050.2,

Nitab4.5_0008185g0030.2 are homologues of Nitab4.5_0013685g0010.2 according to the present invention. RNA binding proteins according to the present invention may contain conserved domains termed an RNA binding domain (RBD) and an RGG domain.

According to the present invention, tobacco industry products with modulated alkaloid content and commercially desirable traits sought after by consumers of tobacco industry products can be produced. In some instances, consumers may desire a product with low levels of alkaloid content. In some instances, consumers may desire a product with low levels of TSNA precursors.

The present invention may be particularly useful in the field of plant molecular farming, where plants (such as tobacco and other Nicotiana spp.) are used for the production of proteins, peptides, and metabolites e.g. for the production of therapeutics and pharmaceuticals such as antibiotics, virus like particles, or neutraceuticals or small molecules. Tobacco has been used for the development of an HIV-neutralising antibody in an EU-funded project called PharmPlant and Medicago Inc., Canada have worked on a tobacco-based platform for the production of virus-like particles for flu vaccine manufacture.

Thus, a plant according to the present invention may be used for molecular farming to reduce or eliminate the presence of nicotinic alkaloids. The use of a low nicotine plant or rootsock is beneficial in molecular farming and would reduce downstream processing costs associated with purification.

The present inventors have surprisingly determined a method for modulating (e.g. decreasing) the alkaloid content, of a plant (e.g. a tobacco plant) by modulating (e.g. decreasing) the activity or expression of a gene encoding an RNA binding protein. The alkaloid content (e.g. the content of one or more of nornicotine, PON, anabasine, anatabine or myosmine, suitably the content of one or more of nornicotine, PON, anabasine or anatabine) of a plant (e.g. tobacco plant) may be decreased by decreasing the activity or expression of a gene encoding an RNA binding protein or may be increased by increasing the activity or expression of gene encoding an RNA binding protein. Prior to the present invention it had not been known that modulation of the activity or expression of a gene encoding an RNA binding protein as described herein could be used to modulate alkaloid content or modulate TSNA precursor content in particular, nornicotine, PON, anabasine and/or anatabine content.

In one aspect, the present invention provides a method of modulating (e.g. reducing) the alkaloid content of a tobacco plant or part thereof or tobacco cell or tobacco cell culture, the method comprising modifying said plant or part thereof or cell by decreasing the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , or a homologue of SEQ ID NO. 1. In one aspect, the present invention provides a method of modulating (e.g. reducing) the alkaloid content of a tobacco plant or part thereof or tobacco cell or tobacco cell culture, the method comprising modifying said plant or part thereof or cell by decreasing the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31.

In another aspect, the present invention provides a method of reducing the content of a tobacco-specific nitrosamine (TSNA) precursor in a tobacco plant or part thereof or tobacco cell or tobacco cell culture, the method comprising modifying said plant or part thereof or cell by decreasing the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , or a sequence which has at least 80% identity to SEQ I D NO. 1 , or a homologue of SEQ I D NO. 1.

In one aspect, the present invention provides a method of reducing the content of a tobacco- specific nitrosamine (TSNA) precursor in a tobacco plant or part thereof or tobacco cell or tobacco cell culture, the method comprising modifying said plant or part thereof or cell by decreasing the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31.

In another aspect, the present invention provides the use of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , for modulating (e.g. decreasing) alkaloid content or reducing TSNA precursor content in a tobacco cell or tobacco plant or part thereof or a tobacco cell culture.

In a further aspect, there is provided a method for producing a plant or part thereof, a tobacco cell or tobacco cell culture, a plant propagation material, a leaf, a cut harvested leaf, a processed leaf or a cut and processed leaf which has modulated (e.g. decreased) alkaloid content or reduced TSNA precursor content, the method comprising modifying said plant or part thereof or cell or cell culture or plant propagation material to decrease the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31.

Suitably, the alkaloid content or TSNA precursor content may be reduced in comparison to a plant or part thereof or cell or cell culture or plant propagation material or leaf which has not been modified to decrease the activity or expression of the at least one gene encoding said RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31.

In another aspect, the present invention provides a plant or part thereof or a cell or cell culture which has been modified to achieve a modulation (e.g. decrease) in alkaloid content or reduction in TSNA precursor content in comparison to an unmodified plant or part thereof or unmodified cell culture, wherein the modification is reduction of the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31.

In one aspect, the present invention provides a plant propagation material obtainable (e.g. obtained) from a plant according to the present invention, or from a plant or cell culture produced by a method according to the present invention.

Suitably, the TSNA precursor may be selected from nornicotine, PON, anabasine and anatabine. Suitably, the TSNA precursor may be nornicotine. Suitably, the TSNA precursor may be PON. Suitably, the TSNA precursor may be anabasine. Suitably, the TSNA precursor may be anatabine.

In one aspect, the present invention provides the use of a plant or part thereof or cell culture according to the present invention, or of a plant produced by a method according to the present invention to breed a plant.

In another aspect, the present invention provides the use of a plant or part thereof or a cell culture according the present invention, or of a plant produced by a method according to the present invention for production of a product.

In a further aspect, the present invention provides the use of a plant or part thereof according to the present invention, or of a plant produced by a method according to the present invention to grow a crop.

In another aspect, the present invention provides the use of a plant or part thereof according to the present invention, or of a plant produced by a method according to the present invention to produce a leaf.

In a further aspect, the present invention provides a harvested leaf of a plant according to the present invention, or obtainable (e.g. obtained) from a plant propagated from a propagation material according to the present invention, or obtainable (e.g. obtained) from a plant obtained by a use according to the present invention, or obtainable (e.g. obtained) from a plant produced by a method the present invention.

Suitably, the harvested leaf of a plant may be a cut harvested leaf.

In another aspect, the present invention provides a processed leaf, preferably a processed tobacco leaf, preferably a non-viable processed tobacco leaf: obtainable (e.g. obtained) from a plant obtainable (e.g. obtained) from a use according to the present invention;

obtainable (e.g. obtained) by processing a plant according to the present invention;

obtainable (e.g. obtained) from a plant propagated from a plant propagation material according to the present invention; or

obtainable (e.g. obtained) by processing a harvested leaf according to the present invention; or

obtainable (e.g. obtained) from a plant produced by a method the present invention. Suitably, the leaf may be processed by curing, fermenting, pasteurising or a combination thereof.

Suitably, the content of one or more TSNAs selected from N'-nitrosonornicotine (NNN), 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N'-nitrosoanatabine (NAT) and N- nitrosoanabasine (NAB) may be reduced, wherein preferably the content of NNN and/or NNK is reduced, wherein more preferably at least the content of NNN is reduced.

Suitably, the processed leaf may be a cut processed leaf.

In a further aspect, the present invention provides cured tobacco material made from a plant or a part thereof according to the present invention or an extract thereof, or from a leaf according to the present invention, or an extract thereof.

In one aspect, the present invention provides a tobacco blend comprising cured tobacco material according to the present invention.

In one aspect, the present invention provides a tobacco industry product prepared from:

a tobacco plant or a part thereof or a tobacco cell or cell culture according to the present invention;

a tobacco plant or part thereof propagated from a tobacco plant propagation material according to the present invention;

a harvested leaf of a plant according to the present invention;

a processed leaf according to the present invention;

a plant produced by a method the present invention;

cured tobacco according the present invention; or

a tobacco blend according to the present invention.

Suitably, the tobacco industry product may be a combustible smoking article.

Suitably, the tobacco industry product may be a smokeless tobacco product.

Suitably, the tobacco industry product may be a non-combustible aerosol provision system such as a tobacco heating device or an aerosol-generating device.

In another aspect, the present invention provides a combustible smoking article, non combustible aerosol provisioning system, smokeless tobacco product or tobacco heating device comprising a plant or a part thereof according to the present invention, or a tobacco cell or cell culture according to the present invention; or a harvested leaf according to the present invention, or a processed leaf according to the present invention, or a cured tobacco material according to the present invention; or a tobacco blend according to the present invention.

In a further aspect, the present invention provides the use of a nucleotide sequence of at least one gene encoding an RNA binding protein to select a plant having modulated (e.g. decreased) alkaloid content and/or reduced content of a tobacco specific nitrosamine (TSNA) precursor, wherein the sequence of the RNA binding protein is selected from SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 , or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29, 30, 32 or 33, or a sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29, 30, 32 or 33.

In another aspect, the present invention provides a mutant of a plant carrying a heritable mutation in a nucleotide sequence of at least one gene encoding an RNA binding protein wherein the gene is selected from SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29, 30, 32 or 33, or a sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29, 30, 32 or 33, wherein said heritable mutation decreases the activity or expression of the at least one gene encoding an RNA binding protein and wherein the mutant plant has modulated (e.g. decreased) alkaloid content and/or reduced tobacco specific nitrosamine (TSNA) precursor relative to a comparable plant which does not carry said heritable mutation.

In another aspect, the present invention provides progeny or seed of a mutant plant which carries the heritable mutation according to the present invention.

In one aspect, the present invention provides a harvested leaf, a processed leaf or cured tobacco material produced from a plant comprising a modification in a nucleotide sequence of at least one gene encoding an RNA binding protein, wherein the at least one gene is selected from SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29, 30, 32 or 33, or a sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29, 30, 32 or 33, wherein said modification decreases the activity or expression of the at least one gene encoding an RNA binding protein and wherein said plant has modulated (e.g. decreased) alkaloid content and/or reduced tobacco specific nitrosamine (TSNA) precursor content relative to a comparable plant which does not carry said modification in the at least one gene encoding said RNA binding protein. In another aspect, the present invention provides a method, a leaf, a plant, a plant propagation material, a harvested leaf, a processed tobacco, a tobacco product, a use or a combination thereof as described herein with reference to the description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which:

Figure 1 shows the alkaloid content of 5-week-old tobacco leaves overexpressing Nitab4.5_0013685g0010.2. Alkaloid content is represented relative to a control and is representative of two biological replicates analysed by one-way ANOVA and Tukey’s multiple- comparison post-test. Values are shown as means ± SEM. Asterisks indicate statistical significance of P value =¾ 0.01.

Figure 2 shows the alkaloid content of 5-week-old tobacco leaves expressing an artificial miRNA targeting Nitab4.5_0013685g0010.2. Alkaloid content is represented relative to control and comprises two biological replicates analysed by one-way ANOVA and Tukey’s multiple- comparison post-test. Values are shown as means ± SEM. Asterisks indicate statistical significance of P value =¾ 0.01.

Figure 3 shows the alkaloid content of 5-week-old tobacco leaves expressing Nitab4.5_0013685g0010.2_deltaRBD-RGG. Alkaloid content is represented relative to a control and is representative of two biological replicates analysed by one-way ANOVA and Tukey’s multiple-comparison post-test. Values are shown as means ± SEM. Asterisks indicate statistical significance of P value =¾ 0.05.

Figure 4 shows the amino acid sequence of Nitab4.5_0013685g0010.2- SEQ ID NO. 1 - a protein from Nicotiana tabacum according to the present invention.

Figure 5 shows the coding sequence of Nitab4.5_0013685g0010.2- SEQ ID NO. 2 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 6 shows the genomic sequence of Nitab4.5_0013685g0010.2- SEQ ID NO. 3 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 7 shows the amino acid sequence of Nitab4.5_0000308g0150.2 - SEQ ID NO. 4 - a protein from Nicotiana tabacum according to the present invention.

Figure 8 shows the coding sequence of Nitab4.5_0000308g0150.2 - SEQ ID NO. 5 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 9 shows the genomic sequence of Nitab4.5_0000308g0150.2 - SEQ ID NO. 6 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 10 shows the amino acid sequence of Nitab4.5_0003919g0010.2 - SEQ ID NO. 7 - a protein from Nicotiana tabacum according to the present invention. Figure 11 shows the coding sequence of Nitab4.5_0003919g0010.2 - SEQ ID NO. 8 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 12 shows the genomic sequence of Nitab4.5_0003919g0010.2 - SEQ ID NO. 9 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 13 shows the amino acid sequence of Nitab4.5_0002978g0020.2 - SEQ ID NO. 10 - a protein from Nicotiana tabacum according to the present invention.

Figure 14 shows the coding sequence of Nitab4.5_0002978g0020.2 - SEQ ID NO. 11 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 15 shows the genomic sequence of Nitab4.5_0002978g0020.2 - SEQ ID NO. 12 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 16 shows the amino acid sequence of Nitab4.5_0001361g0220.2 - SEQ ID NO. 13 - a protein from Nicotiana tabacum according to the present invention.

Figure 17 shows the coding sequence of Nitab4.5_0001361g0220.2 - SEQ ID NO. 14 - encoding protein from Nicotiana tabacum according to the present invention.

Figure 18 shows the genomic sequence of Nitab4.5_0001361g0220.2 - SEQ ID NO. 15 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 19 shows the amino acid sequence of Nitab4.5_0002978g0030.2 - SEQ ID NO. 16 - protein from Nicotiana tabacum according to the present invention.

Figure 20 shows the coding sequence of Nitab4.5_0002978g0030.2 - SEQ ID NO. 17 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 21 shows the genomic sequence of Nitab4.5_0002978g0030.2 - SEQ ID NO. 18 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 22 shows the amino acid sequence of Nitab4.5_0001361g0225.2 - SEQ ID NO. 19 - a protein from Nicotiana tabacum according to the present invention.

Figure 23 shows the coding sequence of Nitab4.5_0001361g0225.2 - SEQ ID NO. 20 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 24 shows the genomic sequence of Nitab4.5_0001361g0225.2 - SEQ ID NO. 21 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 25 shows the amino acid sequence of Nitab4.5_0003978g0020.2 - SEQ ID NO. 22 - a protein from Nicotiana tabacum according to the present invention.

Figure 26 shows the coding sequence of Nitab4.5_0003978g0020.2 - SEQ ID NO. 23 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 27 shows the genomic sequence of Nitab4.5_0003978g0020.2 - SEQ ID NO. 24 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 28 shows the amino acid sequence of Nitab4.5_0000078g0240.2 - SEQ ID NO. 25 - a protein from Nicotiana tabacum according to the present invention. Figure 29 shows the coding sequence of Nitab4.5_0000078g0240.2 - SEQ ID NO. 26 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 30 shows the genomic sequence of Nitab4.5_0000078g0240.2- SEQ ID NO. 27 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 31 shows the amino acid sequence of Nitab4.5_0005079g0050.2 - SEQ ID NO. 28 - a protein from Nicotiana tabacum according to the present invention.

Figure 32 shows the coding sequence of Nitab4.5_0005079g0050.2 - SEQ ID NO. 29 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 33 shows the genomic sequence of Nitab4.5_0005079g0050.2 - SEQ ID NO. 30 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 34 shows the amino acid sequence of Nitab4.5_0008185g0030.2 - SEQ ID NO. 31 - a protein from Nicotiana tabacum according to the present invention.

Figure 35 shows the coding sequence of Nitab4.5_0008185g0030.2 - SEQ ID NO. 32 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 36 shows the genomic sequence of Nitab4.5_0008185g0030.2 - SEQ ID NO. 33 - encoding a protein from Nicotiana tabacum according to the present invention.

Figure 37 shows SEQ ID NO. 34 which corresponds to the nucleotide sequence of Nitab4.5_0013685g0010.2_deltaRBD-RGG as described in Example 3.

Figure 38 shows SEQ ID NO. 35 which corresponds to the amino acid sequence of Nitab4.5_0013685g0010.2_deltaRBD-RGG as described in Example 3.

Figure 39 shows SEQ ID NO. 36 which corresponds to the amino acid sequence of an RNA- binding domain (RBD) (amino acid residues 6-84 of SEQ ID NO. 1).

Figure 40 shows SEQ ID NO. 37 which corresponds to an RGG motif (amino acid residues 97- 99 of SEQ ID NO. 1).

Figure 41 shows SEQ ID NO. 38 which corresponds to the amino acid sequence of Nitab4.5_0005487g0030.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 42 shows SEQ ID NO. 39 which corresponds to the coding sequence of

Nitab4.5_0005487g0030.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 43 shows SEQ ID NO. 40 which corresponds to the genomic acid sequence of Nitab4.5_0005487g0030.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 44 shows SEQ ID NO. 41 which corresponds to the amino acid sequence of Nitab4.5_0007831g0020.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 45 shows SEQ ID NO. 42 which corresponds to the coding sequence of

Nitab4.5_0007831g0020.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 46 shows SEQ ID NO. 43 which corresponds to the genomic sequence of

Nitab4.5_0007831g0020.2, an interactor of Nitab4.5_0013685g0010.2. Figure 47 shows SEQ ID NO. 44 which corresponds to the amino acid sequence of Nitab4.5_0002978g0020.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 48 shows SEQ ID NO. 45 which corresponds to the coding sequence of

Nitab4.5_0002978g0020.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 49 shows SEQ ID NO. 46 which corresponds to the genomic sequence of

Nitab4.5_0002978g0020.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 50 shows SEQ ID NO. 47 which corresponds to the amino acid sequence of Nitab4.5_0005552g0010.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 51 shows SEQ ID NO. 48 which corresponds to the coding sequence of

Nitab4.5_0005552g0010.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 52 shows SEQ ID NO. 49, which corresponds to the genomic sequence of

Nitab4.5_0005552g0010.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 53 shows SEQ ID NO. 50, which corresponds to the amino acid sequence of Nitab4.5_0003679g0060.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 54 shows SEQ ID NO. 51 , which corresponds to the coding sequence of

Nitab4.5_0003679g0060.2, an interactor of Nitab4.5_0013685g0010.2.

Figure 55 shows SEQ ID NO. 52, which corresponds to the genomic sequence of

Nitab4.5_0003679g0060.2, an interactor of Nitab4.5_0013685g0010.2.

SEQUENCE LISTING

A summary of sequence identifiers used throughout the subject specification and the corresponding sequence listing is provided wherein:

SEQ ID NO. 1 corresponds to the amino acid sequence of Nitab4.5_0013685g0010.2.

SEQ ID NO. 2 corresponds to the coding sequence of Nitab4.5_0013685g0010.2.

SEQ ID NO. 3 corresponds to the genomic sequence of Nitab4.5_0013685g0010.2.

SEQ ID NO. 4 corresponds to the amino acid sequence of Nitab4.5_0000308g0150.2.

SEQ ID NO. 5 corresponds to the coding sequence of Nitab4.5_0000308g0150.2.

SEQ ID NO. 6 corresponds to the genomic sequence of Nitab4.5_0000308g0150.2.

SEQ ID NO. 7 corresponds to the amino acid sequence of Nitab4.5_0003919g0010.2.

SEQ ID NO. 8 corresponds to the coding sequence of Nitab4.5_0003919g0010.2.

SEQ ID NO. 9 corresponds to the genomic sequence of Nitab4.5_0003919g0010.2.

SEQ ID NO. 10 corresponds to the amino acid sequence of Nitab4.5_0002978g0020.2.

SEQ ID NO. 11 corresponds to the coding sequence of Nitab4.5_0002978g0020.2.

SEQ ID NO. 12 corresponds to the genomic sequence of Nitab4.5_0002978g0020.2.

SEQ ID NO. 13 corresponds to the amino acid sequence of Nitab4.5_0001361g0220.2.

SEQ ID NO. 14 corresponds to the coding sequence of Nitab4.5_0001361g0220.2. SEQ ID NO. 15 corresponds to the genomic sequence of Nitab4.5_0001361g0220.2.

SEQ ID NO. 16 corresponds to the amino acid sequence of Nitab4.5_0002978g0030.2.

SEQ ID NO. 17 corresponds to the coding sequence of Nitab4.5_0002978g0030.2.

SEQ ID NO. 18 corresponds to the genomic sequence of Nitab4.5_0002978g0030.2.

SEQ ID NO. 19 corresponds to the amino acid sequence of Nitab4.5_0001361g0225.2.

SEQ ID NO. 20 corresponds to the coding sequence of Nitab4.5_0001361g0225.2.

SEQ ID NO. 21 corresponds to the genomic sequence of Nitab4.5_0001361g0225.2.

SEQ ID NO. 22 corresponds to the amino acid sequence of Nitab4.5_0003978g0020.2.

SEQ ID NO. 23 corresponds to the coding sequence of Nitab4.5_0003978g0020.2.

SEQ ID NO. 24 corresponds to the genomic sequence of Nitab4.5_0003978g0020.2.

SEQ ID NO. 25 corresponds to the amino acid sequence of Nitab4.5_0000078g0240.2.

SEQ ID NO. 26 corresponds to the coding sequence of Nitab4.5_0000078g0240.2.

SEQ ID NO. 27 corresponds to the genomic sequence of Nitab4.5_0000078g0240.2.

SEQ ID NO. 28 corresponds to the amino acid sequence of Nitab4.5_0005079g0050.2.

SEQ ID NO. 29 corresponds to the coding sequence of Nitab4.5_0005079g0050.2.

SEQ ID NO. 30 corresponds to the genomic sequence of Nitab4.5_0005079g0050.2.

SEQ ID NO. 31 corresponds to the amino acid sequence of Nitab4.5_0008185g0030.2.

SEQ ID NO. 32 corresponds to the coding sequence of Nitab4.5_0008185g0030.2.

SEQ ID NO. 33 corresponds to the genomic sequence of Nitab4.5_0008185g0030.2.

SEQ ID NO. 34 corresponds to the nucleotide sequence of Nitab4.5_0013685g0010.2_deltaRBD-RGG as described in Example 3.

SEQ ID NO. 35 corresponds to the amino acid sequence of Nitab4.5_0013685g0010.2_deltaRBD-RGG as described in Example 3.

SEQ ID NO. 36 corresponds to the amino acid sequence of an RNA-binding domain (RBD) (amino acid residues 6-84 of SEQ ID NO. 1).

SEQ ID NO. 37 corresponds to an RGG motif (amino acid residues 97-99 of SEQ ID NO. 1). SEQ ID NO. 38 corresponds to the amino acid sequence of Nitab4.5_0005487g0030.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 39 corresponds to the coding sequence of Nitab4.5_0005487g0030.2, an interactor of N itab4.5_0013685g0010.2.

SEQ ID NO. 40 corresponds to the genomic sequence of Nitab4.5_0005487g0030.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 41 corresponds to the amino acid sequence of Nitab4.5_0007831g0020.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 42 corresponds to the coding sequence of Nitab4.5_0007831g0020.2, an interactor of N itab4.5_0013685g0010.2. SEQ ID NO. 43 corresponds to the genomic sequence of Nitab4.5_0007831g0020.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 44 corresponds to the amino acid sequence of Nitab4.5_0002978g0020.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 45 corresponds to the coding sequence of Nitab4.5_0002978g0020.2, an interactor of N itab4.5_0013685g0010.2.

SEQ ID NO. 46 corresponds to the genomic sequence of Nitab4.5_0002978g0020.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 47 corresponds to the amino acid sequence ofNitab4.5_0005552g0010.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 48 corresponds to the coding sequence ofNitab4.5_0005552g0010.2, an interactor of N itab4.5_0013685g0010.2.

SEQ ID NO. 49 corresponds to the genomic sequence ofNitab4.5_0005552g0010.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 50 corresponds to the amino acid sequence of Nitab4.5_0003679g0060.2, an interactor of Nitab4.5_0013685g0010.2.

SEQ ID NO. 51 corresponds to the coding sequence of Nitab4.5_0003679g0060.2, an interactor of N itab4.5_0013685g0010.2.

SEQ ID NO. 52 corresponds to the genomic sequence of Nitab4.5_0003679g0060.2, an interactor of Nitab4.5_0013685g0010.2.

Some sequences disclosed herein contain“X” or“N” in nucleotide sequences.“X” or“N” can be any nucleotide or a deletion or insertion of one or more nucleotides. For example, in some cases a string of “X”s or“N”s are shown. The number of “X”s or“N”s does not necessarily correlate with the actual number of nucleotides at that position. There may be more or fewer nucleotides than shown as“X” or“N” in the sequence.

DETAILED DESCRIPTION

For the first time the present inventors have shown that by modulating the activity or expression of at least one gene encoding an RNA binding protein in a plant (e.g. a tobacco plant) or a cell (e.g. tobacco cell), the alkaloid and/or TSNA precursor content of the plant (or processed plant) or cell can be modulated.

The present invention provides a method of modulating (e.g. decreasing) the alkaloid content of a plant or a part thereof, the method comprising modifying said plant by modulating (e.g. decreasing) the activity or expression of at least one gene encoding an RNA binding protein. Also provided is a method of modulating (e.g. decreasing) the content of a tobacco specific nitrosamine (TSNA) precursor in a tobacco plant or plant part thereof, the method comprising modifying said plant by modulating (e.g. decreasing) the activity or expression of at least one gene encoding an RNA binding.

The at least one gene encoding an RNA binding protein may be selected from at least one gene encoding an amino acid sequence as set out in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA bindingprotein may comprise a nucleotide sequence as set out in SEQ ID NO. NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30.

Suitably, the protein may comprise an RNA binding domain and/or an RGG domain.. Suitably, the protein may comprise an RNA binding domain and an RGG domain. In one embodiment at least two genes encoding RNA binding proteins are modified selected from the group of: genes which encode polypeptides comprising an amino acid sequence as set out in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28 or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or genes encoding an RNA binding protein comprising a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30.

In one embodiment at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight, such as at least nine, such as ten genes encoding RNA binding proteins are modulated, wherein the genes are selected from those which encode polypeptides comprising an amino acid sequence as set out in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28 or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30. Suitably, the protein may comprise an RNA binding protein and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain. In one aspect, the at least one gene encoding an RNA binding protein encodes a polypeptide which comprises an amino acid sequence as set out in: SEQ ID NO. 1 or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 ; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2 or 3 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2 or 3; or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2 or 3. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

In one aspect, the activity or expression of at least one further gene is modulated. Suitably, at least two (or at least three or at least four or at least five or at least six or at least seven or at least eight or at least nine) additional genes selected from SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12,

14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 27 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14,

15, 17, 18, 20, 21 , 23, 24, 27 or 30 may also be modulated. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

The “expression” of a gene encoding an RNA binding protein may refer to the level of transcription, translation i.e. protein expression.

Measurement of the level or amount of a gene product may be carried out by any suitable method, for example comparison of mRNA transcript levels, protein or peptide levels, and/or phenotype of a plant, between a modified plant and comparable plant which has not been modified according to the present invention.

The term“a comparable product” as defined herein would be one derived from a plant (e.g. a tobacco plant) which had not been modified according to the present invention, but in which all other relevant features were the same (e.g. plant species, growing conditions, method of processing the plant, e.g. tobacco, etc.). The comparable product according to the present invention may mean a plant (e.g. a tobacco plant) or a part thereof, such as a leaf (e.g. a tobacco leaf), a harvested leaf (e.g. a harvested tobacco leaf), a cut harvested leaf (e.g. a cut harvested tobacco leaf), a processed leaf (e.g. a processed tobacco leaf) or plant propagation material (e.g. tobacco plant propagation material), or a product comprising said plant or part therefore, e.g. a tobacco industry product or combinations thereof obtainable or obtained from a plant which has not been modified in accordance with the present invention, e.g. to modulate the activity or expression of gene encoding an RNA binding protein. In one embodiment a comparable product is one which does not comprise gene encoding an RNA binding protein whose activity or expression has been modulated.

The term“modifying” or“modified” as used herein means a plant (e.g. a tobacco plant) or nucleic acid sequence that has been altered or changed. The present invention comprises the modification of plants using techniques for genetic modification of plants or non-genetic modification of plants. Such methods are well known in the art and examples of genetic modification techniques include transformation, transgenics, cisgenics, and gene editing methods. Examples of non-genetic modification techniques include fast-neutron mutagenesis, chemical mutagenesis e.g. ethyl methanesulfonate (EMS) mutagenesis and modern population analysis approaches.

In one embodiment a natural variant which has a modified gene encoding an RNA binding protein is selected and that trait or gene is bred into a second plant which may have commercially desirable traits.

In one embodiment the plant according to the present invention is a transgenic plant. In one embodiment the plant according to the invention is a non-transgenic plant.

The term“unmodified plant” as defined herein would be a plant (e.g. a tobacco plant) which had not been modified according to the present invention, e.g. to modulate the activity or expression of a gene encoding an RNA binding protein or to modify the nucleic acid sequence of at least one gene encoding an RNA binding protein; and in which all other relevant features were the same (e.g. plant species, growing conditions, method of processing tobacco, etc.). In one embodiment an unmodified plant is one which does not comprise a gene encoding an RNA binding protein whose activity or expression has been modulated. In one embodiment, an unmodified plant is one which does not comprise a modified nucleic acid sequence which encodes at least one gene encoding an RNA binding protein.

RNA binding protein

An“RNA binding protein” as used herein has its usual meaning in the art and refers to a protein which is capable of binding RNA. Methods for measuring binding between proteins and RNA are known in the art and include, for example electrophoretic mobility shift assays.

An illustrative sequence of an RNA binding protein from tobacco is shown in SEQ ID NO. 1.

An“RNA binding domain” as used herein has its usual meaning in the art and refers to the common protein structural domain which binds single stranded RNA.

The RNA binding domain contributes to RNA binding.

An illustrative sequence of an RNA binding domain is set forth at amino acids 6-84 of SEQ ID NO. 1 and is also presented as SEQ ID NO. 35. An RNA binding domain may be identified by comparing the protein in question to SEQ ID NO. 35 and/or SEQ ID NO. 1.

Suitably, an RNA binding domain as used herein may refer to a sequence set forth in SEQ ID NO. 35 or a sequence which has at least 80% identity thereto. Suitably, an RNA binding domain as used herein may refer to a sequence which corresponds to amino acids 6-84 of SEQ ID NO. 1 when aligned with SEQ ID NO. 1.

An“RGG domain” or“RGG motif’ as used herein has its usual meaning in the art and refers to an RGG sequence (SEQ ID NO. 36). The RGG domain or motif is a common feature in numerous RNA binding proteins.

An illustrative sequence of an RGG domain is set forth at amino acids 97-99 of SEQ ID NO. 1 and is also presented as SEQ ID NO. 36.

An RGG domain may be identified by comparing the protein in question to SEQ ID NO. 36 and/or SEQ ID NO. 1.

Domains within the amino acid sequence of a protein may be identified using domain prediction software known in the art. Domains are also described in protein databases such as UniprotKB. Without wishing to be bound by theory, it is hypothesized that modulating content of an RNA binding protein in a plant cell or modulating activity, such as RNA binding activity, of an RNA binding protein in a plant would alter the metabolic pathways producing alkaloids and TSNA precursors such as nornicotine and/or PON, resulting in modulated alkaloid and/or TSNA precursor content.

In one embodiment an RNA binding protein comprises an amino acid sequence shown as SEQ ID NO. 1 or a sequence which has at least 80% identity thereto, or a homologue thereof. The protein comprises an RNA binding domain and an RGG domain. Suitably, a homologue of SEQ ID NO. 1 may be selected from the group comprising: SEQ ID NO. 4, 7, 10, 13, 16, 19, 22 25 or 28, or a sequence which has at least 80% identity thereto. Suitably, a homologue of SEQ ID NO. 1 may be selected from the group comprising: SEQ ID NO. 4, 7, 10, 13, 16, 19, 22, 25 or 28, wherein said sequence comprises an RNA binding domain and an RGG domain, or a sequence which has at least 80% identity to SEQ ID NO. 4, 7, 10, 13, 16, 19, 22, 25 or 28 and comprises an RNA binding domain and an RGG domain.

In one embodiment an RNA binding protein comprises an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22 25 or 28, or a sequence which has at least 80% identity thereto (preferably at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). In one embodiment an RNA binding protein comprises an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22 25 or 28, or a sequence which has at least 80% identity thereto (preferably at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto) and comprises an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 1 , or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 4, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 7, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 10, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 13, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 16, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 19, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 22, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 25, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, an RNA binding protein according to the present invention may comprise an amino acid sequence shown as SEQ ID NO. 28, or a sequence which has at least 80% identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

In one embodiment the RNA binding protein according to the present invention comprises or consists of an amino acid sequence selected from: SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28.

Suitably, the protein may be from Nicotiana tabacum.

In one embodiment the at least one RNA binding protein is encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30; or a sequence which has at least 80% sequence identity thereto. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain. Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 2, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 3, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 5, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 6, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 8, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain. Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 9, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 11 , or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 12, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 14, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 15, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain. Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 17, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 18, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 20, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 21 , or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 23, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain. Suitably, the RNA binding for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 24, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 26, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 27, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 29, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

Suitably, the RNA binding protein for use according to the present invention may be encoded by a polynucleotide sequence wherein the gene (prior to mutation) comprises the sequence shown as SEQ ID NO. 30, or a sequence which has at least 80% sequence identity thereto (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, at least, 96%, at least 97%, at least 98%, or at least 99% identity thereto). Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain. In one embodiment the at least RNA binding protein is encoded by a polynucleotide sequence wherein the gene (prior to mutation) is selected from: SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30.

Suitably, the protein for use according to the present invention may be encoded by a polynucleotide sequence from Nicotiana tabacum.

In one aspect the present invention provides a method of decreasing the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein.

In one aspect the present invention provides a method of decreasing the alkaloid content of a plant or part thereof or plant cell, the method comprising modifying said plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a sequence which has at least 80% identity thereto or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

In one aspect the present invention provides a method of decreasing the content of a tobacco specific nitrosamine (TSNA) precursor in a plant or part thereof (e.g. leaf), the method comprising modifying said plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein.

In one aspect the present invention provides a method of decreasing the content of a tobacco specific nitrosamine (TSNA) precursor in a plant or part thereof (e.g. leaf), the method comprising modifying said plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein comprising the amino acid sequence shown as SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a sequence which has at least 80% identity thereto, or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

In one aspect the present invention provides a method of decreasing the content of a TSNA in a processed leaf, such as a cured leaf, the method comprising:

modifying a plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein;

harvesting a leaf from said plant;

and processing e.g. curing said harvested leaf.

Suitably, the method of decreasing the content of a TSNA in a processed leaf may comprise: modifying said plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein comprising the amino acid sequence shown as SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a sequence which has at least 80% identity thereto, or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain.

The term“decreasing” or“inhibiting” (e.g. inhibiting the activity or expression of gene encoding an RNA binding protein) as used herein means that the activity or expression of the gene encoding the RNA binding protein is lower or decreased compared with the activity or expression of the gene in a comparable product.

In one aspect the present invention provides a method of increasing the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by increasing or enhancing the activity or expression of at least one gene encoding an RNA binding protein.

In one aspect the present invention provides a method of increasing the alkaloid content of a plant or part thereof or plant cell, the method comprising modifying said plant by increasing or enhancing the activity or expression of at least one gene encoding an RNA binding protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a sequence which has at least 80% identity thereto or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30. Suitably, the protein may comprise an RNA binding domain and/or an RGG domain. Suitably, the protein may comprise an RNA binding domain and an RGG domain In one aspect the present invention provides a method of increasing the content of a tobacco specific nitrosamine (TSNA) precursor in a plant or part thereof (e.g. leaf), the method comprising modifying said plant by increasing or enhancing the activity or expression of at least one gene encoding an RNA binding protein.

In one aspect the present invention provides a method of increasing the content of a tobacco specific nitrosamine (TSNA) precursor in a plant or part thereof (e.g. leaf), the method comprising modifying said plant by increasing or enhancing the activity or expression of at least one gene encoding an RNA binding protein comprising the amino acid sequence shown as SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a sequence which has at least 80% identity thereto, or wherein the at least one gene encoding an RNA binding comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30.

The term “increasing” or “enhancing” (e.g. increasing the activity or expression of gene encoding an RNA binding protein) as used herein means that the activity or expression of the gene encoding the RNA binding protein is higher or increased compared with the activity or expression of the gene in a comparable product.

According to the present invention, the activity or expression of a gene encoding an RNA binding protein is modulated.

In one aspect the present invention provides a method of modulating (i.e. increasing or decreasing) the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by modulating (i.e. increasing or decreasing) the activity of at least one gene encoding an RNA binding protein.

The term“activity” refers to any functionality of the RNA binding protein encoded by the at least one gene. Examples of activity include the formation of protein: protein interactions, enzymatic activity or localization of the RNA binding protein.

Suitably, the activity may be the ability of the RNA binding protein to interact with another molecule or molecules. In some embodiments the invention provides a method of modulating (i.e. increasing or decreasing) the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by modulating (i.e. increasing or decreasing) the ability of an RNA binding protein to interact with another molecule. Suitably, the ability of the RNA binding protein to interact with the other molecule may be the ability to bind the other molecule. The other molecule may be a protein, such as another RNA binding protein. Suitably, the other molecule may be more than one molecule, such as one or more molecules, such as two or more molecules, such as three or more molecules. Where the other molecule is more than one molecule, the other molecules may be the same molecule or may be different molecules. Suitably, the other molecule may be RNA.

Suitably, the activity may be the ability of the RNA binding protein to bind RNA. In some embodiments the invention provides a method of modulating (i.e. increasing or decreasing) the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by modulating (i.e. increasing or decreasing) the ability of an RNA binding protein to bind RNA.

Modulation of the activity of a gene encoding an RNA binding protein may entail increasing or decreasing the activity of the RNA binding protein.

Increasing the activity of a RNA binding protein refers to enhancing or improving the ability of the RNA binding protein to carry out a particular function in comparison to RNA binding protein in a plant that has not been modified in accordance with the invention.

Decreasing the activity of a RNA binding domain-containing protein refers to reducing, inhibiting or disrupting the ability of the RNA binding protein to carry out a particular function in comparison to a RNA binding protein in a plant that has not been modified in accordance with the invention. The activity of a RNA binding domain-containing protein may be reduced to such an extent that the activity is prevented or eliminated.

In some embodiments the activity of a RNA binding protein may be modulated (i.e. increased or decreased) by at least about 10% 20% 30%, or 40%, suitably at least about 50%, 60%, 70%, more suitably at least about 80%, 90%, 95% or 100% in comparison to the activity of a gene encoding an RNA binding protein in a plant (e.g. a tobacco plant) which has not been modified in accordance with the present invention.

In some embodiments the modulated RNA binding protein exhibits increased or decreased activity compared to an unmodified RNA binding protein. The modulated RNA binding protein may exhibit at least about 1 %, at least about 3%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90% increased or decreased activity compared to an unmodified RNA binding protein.

Techniques are known in the art for measuring protein activities. For example, assays are known for measuring the enzymatic activity of a protein and the localization of a protein can be identified using microscopy techniques. In particular, the ability of an RNA binding protein to bind another molecule may be measured using techniques known in the art. Examples of such techniques include immunoprecipitation, isothermal calorimetry, surface plasmon resonance and microscale thermophoresis. For example, the ability of a modulated or mutated RNA binding protein to bind other molecules may be determined for example by performing co-immunoprecipitation experiments using a modulated or mutated RNA binding protein and a corresponding unmodified or unmutated RNA binding protein. If the modulation or mutation in the RNA binding protein reduces, inhibits or eliminates the ability of the RNA binding protein to bind other molecules, the co- immunoprecipitation will show that the modulated or mutated RNA binding protein binds fewer other molecules.

The ability of an RNA binding protein to bind RNA may be measured using techniques known in the art. Examples of such techniques include techniques such as a bandshift assay (e.g. RNA- electrophoretic mobility shift assay), RNA pull down assay using affinity tags, RNA immunoprecipitation followed by RT-PCR or a non-specific assay such as a poly(A) northern or oligonucleotide-targeted RNase H protection assays.

In one aspect the present invention provides a method of modulating (i.e. increasing or decreasing) the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by modulating (i.e. increasing or decreasing) the expression of at least one gene encoding an RNA binding protein.

The“expression” of a gene refers to the degree to which the information encoded in the gene is converted to a functionality. The level of expression of a gene may be equated with the amount of the product of that gene present in a cell or organism. A modification that modulates (i.e. increases or decreases) the expression of a gene is one that increases the amount of the product of that gene in a plant or cell in comparison to an unmodified plant or cell.

In some embodiments the expression of an RNA binding protein is modulated (i.e. increased or decreased) in comparison to the expression of a gene encoding an RNA binding protein in a plant (e.g. a tobacco plant) which has not been modified in accordance with the present invention.

In some embodiments the expression of an RNA binding protein may be modulated (i.e. increased or decreased) by at least about 10% 20% 30%, or 40%, suitably at least about 50%, 60%, 70%, more suitably at least about 80%, 90%, 95% or 100% in comparison to the expression of a gene encoding an RNA binding protein in a plant (e.g. a tobacco plant) which has not been modified in accordance with the present invention.

In some embodiments the modulated RNA binding protein exhibits increased or decreased expression compared to an unmodified RNA binding protein. The modulated RNA binding protein may exhibit at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90% increased or decreased expression compared to an unmodified RNA binding protein.

Typically, genes are transcribed to mRNA, which is translated to protein, the final gene product. Proteins may be sequestered in cellular stores and/or degraded. The expression of a gene may be modulated by modulating any or all of these steps. Accordingly, in some embodiments the modification modulates expression of at least one gene encoding an RNA binding protein in one of the following ways:

modulating transcription from the at least one gene encoding an RNA binding protein;

modulating translation of the mRNA from the at least one gene encoding an RNA binding protein;

modulating release of the RNA binding protein from intracellular stores; and/or

modulating the rate of degradation of the RNA binding protein.

The expression of specific genes encoding RNA binding proteins can be measured by measuring transcription and/or translation of the gene. Methods for measuring transcription are well known in the art and include, amongst others, northern blot, RNA-Seq, in situ hybridization, DNA microarrays and RT-PCR. Alternatively, the expression of a gene may be measured indirectly by measuring the level of the gene product for example the protein encoded by said gene. For example, the expression of an RNA binding protein may be determined by measuring the presence of the protein using an antibody specific for the RNA binding protein (for example antibodies specific for an RNA binding domain) by western blot.

Modifying

The plant or cell may be modified in any way that modulates activity or expression of at least one gene encoding an RNA binding protein. Types of modifications to plants and cells that modulate activity or expression of genes, as well as techniques to achieve those modifications, are known in the art.

In some embodiments the present invention provides a method of decreasing the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein as described herein.

In some embodiments the present invention provides a method of decreasing the content of a tobacco specific nitrosamine (TSNA) or a precursor of a TSNA in a tobacco plant or plant part thereof, the method comprising modifying said plant or a cell culture by decreasing the activity or expression of at least one gene encoding an RNA binding protein as described herein. Any method known in the art for decreasing or inhibiting the activity or expression of a gene may be used in the methods according to the present invention.

Suitably, the activity or expression of the gene encoding an RNA binding protein may be reduced, partly inactivated, inhibited, eliminated, knocked out or lost such that the protein activity, expression or function of the gene encoding an RNA binding protein may not be detectable.

In one aspect, the at least one gene encoding an RNA binding protein is knocked out. In other words, the gene encoding an RNA binding protein has been rendered completely inoperative.

By way of example, the present method may comprise:

• providing a mutation in a nucleic acid sequence which encodes a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto;

• providing a mutation in a regulatory region (e.g. a promoter or an enhancer) which contributes to controlling the expression of a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto;

• providing an antisense RNA, siRNA or miRNA which reduces the level of nucleic acid sequence encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto.

Each of the above approaches results in the reduction or prevention of activity or expression of a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO.NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30.

As used herein, the term“mutation” encompasses a natural genetic variant or an engineered variant. In particular, the term “mutation” refers to a variation in the nucleotide sequence encoding the amino acid sequence or in the amino acid sequence compared to the sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, preferably at least 98%, preferably at least 99%) sequence identity thereto. In one embodiment the mutation decreases the alkaloid content of a plant. In another embodiment, the mutation decreases the content of at least one TSNA precursor in a plant or part thereof, or leaf such as a harvested or processed leaf. In one embodiment the mutation decreases the content of one or more TSNAs selected from NNN, NNK, NAT, NAB, preferably NNN and/or NNK content is decreased in a processed leaf. Suitably, the TSNA content is reduced in relation to a comparable product.

In one embodiment, a method according to the present invention may comprise providing a nucleic acid sequence to a plant or part thereof or plant cell, wherein said nucleic acid results in the reduction or elimination of the activity or expression of at least one gene encoding an RNA binding protein.

In one embodiment, a method according to the present invention may comprise providing a nucleic acid sequence to a plant or part thereof or plant cell, wherein said nucleic acid results in the modification of the nucleic acid sequence of at least one gene encoding an RNA binding protein.

Suitably said nucleic acid sequence may be introduced to the plant or part thereof or cell. Suitably an endogenous nucleic acid sequence in the plant or part thereof or cell may be modified to encode the polypeptide according to the present invention (e.g. by gene editing). For example, an endogenous nucleotide sequence may be modified to decrease the activity or expression of at least one gene encoding an RNA binding protein.

In a preferred embodiment, each copy of a nucleic acid sequence encoding a protein comprising a sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a sequence which has at least 80% sequence identity thereto or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 which is present in the plant is modified e.g. mutated as defined herein (e.g. each genomic copy of a gene encoding said protein in a plant is mutated). For example, each copy of the gene in the allotetraploid genome of Nicotiana tabacum may be mutated.

In a preferred embodiment, some or all of the homologues of the RNA binding protein described herein are modified e.g. inhibited or mutated. Suitably, some or all of SEQ ID NO. NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or corresponding sequences which have at least 80% sequence identity thereto are modified e.g. inhibited or mutated. In some embodiments the plant or plant cell according to the present invention is homozygous. Suitably, the plant or plant cell may be homozygous for the modification e.g. inhibition or mutation.

In some embodiments the plant or plant cell according to the present invention expresses only the modified e.g. mutated nucleic acid encoding the RNA binding protein. In other words, in some embodiments no endogenous (or endogenous and functional protein) is present in the plant according to the present invention. In other words, if any endogenous protein is present it is preferably in an inactive form.

In one embodiment the present method may comprise providing a mutation in the nucleic acid sequence shown as SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity thereto.

The mutation may alter the plant genome such that a nucleic acid sequence encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto is completely or partially deleted or otherwise modified to inhibit or eliminate the ability of the RNA binding protein to bind RNA. In some embodiments the mutation does not alter the level or expression of the protein but reduces inhibits or eliminates the ability of the RNA binding protein to bind RNA.

Suitably, the mutation may be in an RNA binding domain of the RNA binding protein. Suitably, the mutation may be in an RGG domain of the RNA binding protein. . Suitably, the RNA binding protein may comprise multiple mutations, each in a different domains for example, at least one mutation in an RNA binding domain and at least one mutation in an RGG domain. In some embodiments, the mutation i modifies the ability of the RNA binding protein to bind RNA. Suitably, the mutation may prevent or reduce RNA binding Suitably, the mutation may prevents or reduces RNA binding and reduce the activity of the RNA binding protein.

The mutation may be in one or more domains of the RNA binding protein, such as in an RNA binding domaindomain and/or an RGG domain. In some embodiments, one or more domains of the RNA binding protein, such as an RNA binding domain and/or an RGG domain, may be mutated thereby modifying the ability of the proteinto bind RNA. In some embodiments, one or more domains, such as an RNA binding domain and/or an RGG domain are deleted from the RNA binding protein.

The mutation may interrupt the nucleic acid sequence which encodes a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto.

The interruption may cause the nucleic acid sequence to not be transcribed and/or translated. The nucleic acid sequence may be interrupted, for example, by deleting or otherwise modifying the ATG start codon of the nucleic acid sequence such that translation of the protein is reduced or prevented.

The nucleic acid sequence may comprise one or more nucleotide change(s) that reduce or prevent expression of the protein or affect protein trafficking. For example, expression of the protein may be reduced or prevented by introduction of one or more pre-mature stop codons, a frame shift, a splice mutation or a non-tolerated amino acid substitution in the open reading frame.

A premature stop codon refers to a mutation which introduces a stop codon into the open reading frame and prevents translation of the entire amino acid sequence. The premature stop codon may be a TAG ("amber"), TAA ("ochre"), or TGA ("opal" or "umber") codon.

A frame-shift mutation (also called a framing error or a reading frame shift) is a mutation caused by indels (insertions or deletions) of a number of nucleotides in a nucleic acid sequence that is not divisible by three. Due to the triplet nature of gene expression by codons, the insertion or deletion can change the reading frame, resulting in a completely different translation from the original. A frameshift mutation will often cause the reading of the codons after the mutation to code for different amino acids. The frameshift mutation will commonly result in the introduction of a premature stop codon.

A splice mutation inserts, deletes or changes a number of nucleotides in the specific site at which splicing takes place during the processing of precursor messenger RNA into mature messenger RNA. The deletion of the splicing site results in one or more introns remaining in mature mRNA and may lead to the production of abnormal proteins.

A non-tolerated amino acid substitution refers to a mutation which causes a non-synonymous amino acid substitution in the protein which results in reduced or ablated function of the protein. Any method known in the art for providing a mutation in a nucleic acid sequence may be used in the method according to the present invention. For example, homologous recombination may be used, in which a vector is created in which the relevant nucleic acid sequence(s) are mutated and used to transform plants or plant cells. Recombinant plants or plant cells expressing the mutated sequence may then be selected.

In one embodiment the mutation introduces a non-tolerated amino acid substitution in a protein comprising an amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a sequence which has at least 80% sequence identity thereto.

In some embodiments, the RNA binding domain may contain a mutation which decreases the expression of the at least one gene encoding an RNA binding protein.

In some embodiments, the RGG domain may contain a mutation which decreases the expression of the at least one gene encoding an RNA binding protein. The mutation may be a deletion, a splice mutant or codon encoding a non-tolerated amino acid substitution.

In one embodiment, the nucleic acid sequence encoding the RNA binding protein may be wholly or partially deleted. The deletion may be continuous, or may comprise a plurality of sections of sequence. The deletion preferably removes a sufficient amount of nucleotide sequence such that the nucleic acid sequence no longer encodes a functional RNA binding protein. The deletion may be total, in which case 100% of the coding portion of the nucleic acid sequence is absent, when compared to the corresponding genome of a comparable unmodified plant. The deletion may, for example, remove at least 50, 60, 70, 80 or 90% of the coding portion of the nucleic acid sequence. Suitably, at least part of the protein may be deleted. The deletion may, for example, remove at least 10, 20, 30, 40, 50, 60, 70, 80 or 90% of the coding portion of the protein.

The deletion may remove at least 10 amino acids (such as at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) from the C terminal of the RNA binding protein. Suitably, the deletion may remove at least 10 amino acids (such as at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) which correspond to the C terminus of the RNA binding protein wherein the sequence of the RNA binding protein is aligned with SEQ ID NO. 1. Suitably, the deletion may remove at least 10 amino acids (such as at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) from the C terminus of the RNA binding protein wherein the RNA binding protein prior to deletion comprises an amino acid sequence set forth in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a sequence which has at least 80% sequence identity thereto. Suitably, the deletion may remove at least 10 amino acids (such as at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) from the C terminus of the RNA binding protein wherein the RNA binding protein prior to deletion comprises an amino acid sequence set forth in SEQ ID NO. 1 , or a sequence which has at least 80% sequence identity thereto.

Suitably, the protein for use according to the present invention may comprise a truncated RNA binding protein. Suitably, the truncated protein may be a truncated version of an amino acid sequence set forth in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a sequence which has at least 80% sequence identity thereto. Suitably, the truncated protein lacks at least 10 amino acids (such as at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) from the C terminus of the RNA binding protein.

The deletion may remove at least part of an RNA binding domain. The deletion may, for example, remove at least 10, 20, 30, 40, 50, 60, 70, 80 or 90% of an RNA binding domain. Suitably, the deletion may remove at least 5 amino acids, at least 10 amino acids, at least 15, at least 20, at least 25, at least 30 amino acids, at least 40 amino acids, at least 50 amino acids, at least 60 amino acids, at least 70 amino acids, at least 80 amino acids of an RNA binding domain. Suitably, the deletion may remove 5 amino acids, 10 amino acids, 15, 20 amino acids, 25 amino acids, 30 amino acids, 40 amino acids, 50 amino acids, 60 amino acids, 70 amino acids, 80 amino acids of an RNA binding domain.

The deletion may remove at least part of an RGG motif. The deletion may, for example, remove at least one or at least two amino acids from an RGG domain. Suitably, the RGG domain may be completely deleted.

In one embodiment, the RNA binding protein is encoded by a nucleotide sequence which comprises or consists of the sequence set forth in SEQ ID NO. 34 or a sequence with at least 80% identity thereto (such as at least 85%, 90%, 95% identity).

In one embodiment, the RNA binding protein comprises or consists of a sequence as set forth in SEQ ID NO. 35, or a sequence with at least 80% identity thereto (such as at least 85%, 90%, 95% identity).

Methods for deletion of nucleic acid sequences in plants are known in the art. For example, homologous recombination may be used, in which a vector is created in which the relevant nucleic acid sequence(s) are missing and used to transform plants or plant cells. Recombinant plants or plant cells expressing the new portion of sequence may then be selected.

Plant cells transformed with a vector as described herein may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.

Modification of the nucleic acid sequence may be performed using targeted mutagenesis methods (also referred to as targeted nucleotide exchange (TNE) or oligo-directed mutagenesis (ODM)). Targeted mutagenesis methods include, without limitation, those employing zinc finger nucleases, TALENs (see WO2011/072246 and WO2010/079430), Cas9-like, Cas9/crRNA/tracrRNA, Cas9/gRNA, or other CRISPR systems (see WO 2014/071006 and WO2014/093622), meganucleases (see W02007/047859 and W02009/059195), or targeted mutagenesis methods employing mutagenic oligonucleotides, possibly containing chemically modified nucleotides for enhancing mutagenesis with sequence complementarity to the gene, into plant protoplasts (e.g., KeyBase® or TALENs).

Alternatively, mutagenesis systems such as TILLING (Targeting Induced Local Lesions IN Genomics; McCallum et al. (2000) Nat. Biotech. 18:455, and McCallum et al. (2000) Plant Physiol. 123, 439-442, both incorporated herein by reference) may be used to generate plant lines which comprise a gene encoding a protein having a mutation. TILLING uses traditional chemical mutagenesis (e.g. ethyl methanesulfonate (EMS) mutagenesis, which produces random mutations) followed by high-throughput screening for mutations. Thus, plants, seeds, cells and tissues comprising a gene having the desired mutation may be obtained.

The method may comprise the steps of mutagenizing plant seeds (e.g. EMS mutagenesis), pooling of plant individuals or DNA, PCR amplification of a region of interest, heteroduplex formation and high-throughput detection, identification of the mutant plant, sequencing of the mutant PCR product. It is understood that other mutagenesis and selection methods may equally be used to generate such modified plants. Seeds may, for example, be radiated or chemically treated and the plants may be screened for a modified phenotype.

Fast neutron deletion mutagenesis may be used in a reverse genetics sense (i.e. with PCR) to identify plant lines carrying a deletion in the endogenous gene. See for example Ohshima et al. (1998) Virology 213:472-481 ; Okubara et al. (1994) Genetics 137:867-874; and Quesada et al. (2000) Genetics 154:421-4315 which are incorporated herein by reference.

In another approach, dominant mutants may be used to trigger RNA silencing due to gene inversion and recombination of a duplicated gene locus. See for example Kusaba et al. (2003) Plant Cell 15:1455-1467 (incorporated herein by reference).

Modified plants may be distinguished from non-modified plants, i.e., wild type plants, by molecular methods, such as the mutation(s) present in the DNA, and by the modified phenotypic characteristics. The modified plants may be homozygous or heterozygous for the modification. Preferably modified plants are homozygous for the modification.

In one embodiment the method of reducing or preventing the activity or expression of a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto does not comprise treating the plant with a chemical (e.g. an agrochemical).

Other ways of reducing or preventing the expression will be apparent to one skilled in the art and include the use of virus-induced gene silencing (VIGs), micro RNA silencing, RNAi, antisense, tDNA insertions, or dominant negative constructs (or antimorphic mutations).

In one embodiment the expression of of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by virus-induced gene silencing.

In one embodiment the expression of of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by microRNAs.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by RNAi.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by antisense suppression.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by sense suppression.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by tDNA insertions.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by dominant negative constructs (or antimorphic mutations).

In one embodiment the expression of of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by a targeted mutagenesis based system.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by a gene editing e.g. CRISPR based system.

In one embodiment the expression of a gene encoding a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or an amino acid sequence which has at least 80% sequence identity thereto may be reduced or eliminated by zinc finger nuclease, TALENs, meganucleases, mutagenic oligonucleotides or TILLING.

In some embodiments the present invention provides a method of increasing the alkaloid content of a plant or part thereof or cell (e.g. plant cell), the method comprising modifying said plant by increasing or enhancing the activity or expression of at least one gene encoding an RNA binding protein.

Any method known in the art for increasing or enhancing the activity or expression of a gene may be used in the methods according to the present invention. In some embodiments the method may comprise overexpressing at least one gene encoding an RNA binding protein. Suitably the method may comprise expressing one or more additional copies of the at least one gene encoding an RNA binding protein in the plant or cell. Suitably the method may comprise modifying the endogenous copy of the at least one gene encoding an RNA binding protein such that its expression is increased. The method may comprise mutating the coding sequence of the at least one gene encoding an RNA binding protein. The method may comprise mutating a regulatory sequence that regulates expression of the at least one gene encoding an RNA binding protein.

Suitably the method may comprise transforming a cell of a plant (e.g. a tobacco plant) with a genetic construct which encodes at least one RNA binding protein comprising an amino acid sequence as set out in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30; or which comprises a nucleotide sequence which encodes a protein which is capable of promoting or augmenting at least one endogenous RNA binding protein. It will be appreciated that each of these options would result in an increased activity and expression of the polypeptide encoded by the at least one RNA binding protein. The method may comprise regenerating the plant from the transformed cell. There is provided use of genetic construct which is capable of increasing the activity and/or expression of a polypeptide encoded by at least one gene encoding an RNA binding protein for increasing the alkaloid content (e.g. nicotine content) in a plant or part there of or cell transformed with the construct.

The genetic construct may encode a polypeptide comprising the amino acid SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30. In another embodiment, the invention relates to a method of increasing the alkaloid content of a plant or part thereof or a cell, comprising modifying said plant or cell by increasing the activity of at least one gene encoding an RNA binding protein.

In one embodiment the activity of at least one gene encoding an RNA binding protein may be increased by introducing (or providing) a mutation to at least one gene encoding an RNA binding protein.

Suitably, the activity of at least one gene encoding an RNA binding protein may be increased by introducing a mutation to at least one gene encoding an RNA binding protein which comprises an amino acid sequence as set out in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30.

In some embodiments a modification which increases the activity or expression of at least one gene encoding an RNA binding protein and thereby increases alkaloid content by one of the following:

modulating transcription from the at least one gene encoding an RNA binding protein;

modulating translation of the mRNA from the at least one gene encoding an RNA binding protein;

modulating release of the RNA binding protein from intracellular stores; and/or

modulating the rate of degradation of the RNA binding protein.

In one aspect, the activity and or expression of an RNA binding protein as defined herein may be modulated e.g. decreased by modifying the activity or expression of an interactor protein. Without wishing to be bound by theory, in one aspect the interactor protein may reduce or block the activity and/or expression of said RNA binding protein. For example the interactor protein may bind to and/or sequester the RNA binding protein; thus increasing the activity and/or expression of the interactor protein may reduce the activity and/or expression of the RNA binding protein.

In an alternative aspect, the interactor protein may increase or enhance the activity and/or expression of an RNA binding protein as defined herein. For example the interactor protein may act as a co-factor to the RNA binding protein; thus decreasing the activity and/or expression of the interactor protein may reduce the activity and/or expression of the RNA binding protein. In one aspect, the activity and/or expression of an RNA binding protein may be modulated (e.g. reduced) by modifying the activity and/or expression of an interactor protein.

Suitably the interactor protein may be selected from SEQ ID NO. 38, SEQ ID NO. 41. SEQ ID NO. 44, SEQ ID NO. 47, SEQ ID NO. 50 or variants thereof having at least 80% identity thereto (such as at least 85% identity, at least 90% identity, at least 95%, at least 97% identity, at least 98% identity).

Suitably the interactor protein may have a coding sequence be selected from SEQ ID NO. 39, SEQ ID NO. 42. SEQ ID NO. 45, SEQ ID NO. 48, SEQ ID NO. 51 or variants thereof having at least 80% identity thereto (such as at least 85% identity, at least 90% identity, at least 95%, at least 97% identity, at least 98% identity).

Suitably the interactor protein may be encoded by a nucleotide sequence selected from SEQ ID NO. 40, SEQ ID NO. 43. SEQ ID NO. 46, SEQ ID NO. 49, SEQ ID NO. 52 or variants thereof having at least 80% identity thereto (such as at least 85% identity, at least 90% identity, at least 95%, at least 97% identity, at least 98% identity).

Alkaloid content

In one embodiment the present invention provides a method of modulating the alkaloid content of a plant (e.g. a tobacco plant) or a part thereof, the method comprising modifying said plant by modulating the activity or expression of at least one gene encoding an RNA binding protein.

The term“modulating” is used herein to mean either increasing or decreasing.

The term“increasing alkaloid content” is used herein to mean that the alkaloid content in the product of the present invention (e.g. plant, part thereof (e.g. leaf), processed leaf or a product made from the plant (e.g. a tobacco industry product)) is higher compared with a comparable product which has not been modified in accordance with the present invention.

The term “decreasing alkaloid content” is used herein to mean that alkaloid content in the product of the present invention (e.g. plant, part thereof (e.g. leaf), processed leaf or a product made from the plant (e.g. a tobacco industry product)) is lower compared with a comparable product which has not be modified in accordance with the present invention.

In some embodiments, the modulation of alkaloid content refers to an increase in alkaloid content wherein the activity or expression of at least one gene encoding an RNA binding proteindomain-containing protein is increased (or in other words the protein is overexpressed).

In some embodiments, the modulation of alkaloid content refers to a decrease in alkaloid content wherein the expression of at least one gene encoding an RNA binding protein is decreased or inhibited or eliminated.

In a further aspect, the alkaloid content is measured from leaves. In one aspect the alkaloid content is measured from green leaves. In a further aspect, the alkaloid content is measured from cured leaves, e.g. air-cured, flue-cured, fire-cured or sun-cured leaves. In a further aspect, the alkaloid content is measured from flue-cured leaves. In a further aspect, the alkaloid content is measured from air-cured leaves.

The term“alkaloid content” is used herein to mean the concentration and/or total amount of the entire group of compounds classified as alkaloids or the concentration and/or total amount of one or more compounds classified as alkaloids. Alkaloids typically present in tobacco include nornicotine, PON, anatabine, anabasine, nicotine, and myosmine. In some embodiments the content of one or more alkaloids, such as two or more alkaloids, such as three or more alkaloids, such as four or more alkaloids, such as five or more alkaloids, such as all six alkaloids, selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine is modulated. In some embodiments the content of one or more alkaloids, such as two or more alkaloids, such as three or more alkaloids, such as four or more alkaloids, such as five or more alkaloids, such as all six alkaloids, selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine is increased. In some embodiments the content of one or more alkaloids, such as two or more alkaloids, such as three or more alkaloids, such as four or more alkaloids, such as five or more alkaloids, such as all six alkaloids, selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine is decreased. In some embodiments the total alkaloid content of the plant or cell is modulated. In some embodiments the total alkaloid content is increased. In some embodiments the total alkaloid content is increased.

Any method known in the art for determining the concentration and/or total content of alkaloids may be used. One preferred method for analysing alkaloid content involves the analysis by gas chromatography-flame ionization detection method (GC-FID) or by reversed phase high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS).

In one embodiment there is provided a method for producing a plant (e.g. a tobacco plant) or part thereof, a plant propagation material (e.g. a tobacco plant propagation material), a cell (e.g. a tobacco cell), a leaf (e.g. a tobacco leaf), a harvested leaf (e.g. a harvested tobacco leaf), a cut harvested leaf (e.g. a cut harvested tobacco leaf), a processed leaf (e.g. a processed tobacco leaf), a cut and processed leaf (e.g. a cut and processed tobacco leaf), a product comprising said plant or part thereof (e.g. a tobacco industry product) or combinations thereof obtainable or obtained by a plant of the invention which has modulated alkaloid content, the method comprising modifying said plant to modulate the activity or expression of a gene encoding an RNA binding protein. The modulated alkaloid content may be determined by comparing the alkaloid content in the plant (e.g. tobacco plant) or part thereof, plant propagation material (e.g. tobacco plant propagation material), a cell (e.g. a tobacco cell), leaf (e.g. tobacco leaf), harvested leaf (e.g. a harvested tobacco leaf), cut harvested leaf (e.g. a cut harvested tobacco leaf), processed leaf (e.g. processed tobacco leaf), cut and processed leaf (e.g. cut and processed tobacco leaf), a product comprising a plant or part thereof of the present invention, e.g. a tobacco industry product, or combinations thereof with a comparable product.

Suitably the alkaloid content may be modulated in a plant, e.g. a tobacco plant e.g. modified tobacco plant. Suitably the alkaloid content may be modulated in a leaf (e.g. a tobacco leaf e.g. a tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in a harvested leaf (e.g. a harvested tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in a cut harvested leaf (e.g. a cut harvested tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in a processed leaf (e.g. a processed tobacco leaf e.g. a processed tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in a cut and processed leaf (e.g. a cut and processed tobacco leaf e.g. a cut and processed tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in a cured leaf (e.g. cured a tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in an extract of a green leaf (e.g. a green tobacco leaf from a modified tobacco plant). Suitably the alkaloid content may be modulated in a product comprising the plant of the present invention or part thereof (e.g. a tobacco industry product, for example a tobacco industry product produced from a modified tobacco plant or part thereof). Suitably the alkaloid content may be modulated in any one of the above products or combinations thereof. Suitably the modulation of alkaloid content described above may be an increase in alkaloid content. Suitably the modulation of alkaloid content described above may be a decrease in alkaloid content (e.g. a decrease in nornicotine and/or PON content).

In one embodiment the content of one or more alkaloids selected from nornicotine, PON, anatabine and anabasine is decreased. In one embodiment the content of nornicotine is decreased. In one embodiment the content of PON is decreased. In one embodiment the content of anatabine is decreased. In one embodiment the content of anabasine is decreased.

In one embodiment the nicotine content of a modified plant (e.g. tobacco plant), plant propagation material (e.g. tobacco plant propagation material), leaf (e.g. tobacco leaf), harvested leaf (e.g. harvested tobacco leaf), cut harvested leaf (e.g. cut harvested tobacco leaf), processed leaf (e.g. processed tobacco leaf), cut and processed leaf (e.g. cut and processed tobacco leaf) or tobacco industry product from a modified tobacco plant is not substantially decreased. Suitably, the nicotine content is at least 85% (such as at least 90%, such as at least 95%, such as at least 98%, such as at least 99%) of the nicotine content of a comparable product.

In one embodiment the alkaloid content of a plant (e.g. tobacco plant) or part thereof may be modulated by at least 0.5, 1.5, 2, 3 or 4 fold when compared to the alkaloid content of a plant (e.g. tobacco plant) or part thereof, respectively, which has not been modified to modulate the activity or expression of at least one gene encoding an RNA binding protein and which has been grown under similar growth conditions. Suitably the alkaloid content may be modulated by about 0.5 fold to about 4 fold. Suitably the alkaloid content may be modulated by about 4 fold. Suitably the modification may be an increase or a decrease in alkaloid content. Suitably the modulation may be of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine. Suitably the modulation may be of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine and anabasine. Suitably, the nornicotine content may be reduced. Suitably, the PON content may be reduced. Suitably, the anatabine content may be reduced. Suitably, the anabasine content may be reduced.

In one embodiment of the invention the alkaloid content of a plant (e.g. a tobacco plant) or part thereof may be modulated by at least 1%, 2%, 5%, 8%, 10%, 12%, 15%, 20%, 25%, 30%, 40%, 50%, 60 %, 70%, 80%, 90% or 100% in comparison to a plant (e.g. a tobacco plant) or part thereof which has not been modified according to the present invention. In one embodiment the alkaloid content may be modulated by at least 30% in comparison to an unmodified plant or part thereof. In one embodiment the alkaloid content may be modulated by at least 40% in comparison to an unmodified plant or part thereof. In one embodiment the alkaloid content may be modulated by at least 50% in comparison to an unmodified plant or part thereof. In one embodiment the alkaloid content may be modulated by at least 60% in comparison to an unmodified plant or part thereof. The modulation may be an increase or a decrease in alkaloid content when compared to an unmodified plant (e.g. a tobacco plant) or part thereof.

Suitably the modulation may be of total alkaloid content. Suitably the modulation may be of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine. Suitably the modulation may be of one or more alkaloids selected from nornicotine, nicotine, PON, anatabine and anabasine. Suitably the modulation may be of nornicotine content, such as decrease in nornicotine content. Suitably the modulation may be of anabasine content, such as decrease in anabasine content. Suitably the modulation may be of PON content, such as decrease in PON content. Suitably the modulation may be of anatabine content, such as decrease in anatabine content.

Suitably the modulation may be of more than one alkaloid, such as two or more alkaloids, such as three or more alkaloids, such as four or more alkaloids, such as five or more alkaloids, such as all six alkaloids, selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine.

In some embodiments the alkaloid content of the plant may be modulated by between about 5% and about 100%, by between about 10% and about 90%, by between about 20% and about 80%, by between about 30% and about 70%, by between about 40% and 60%, by between about 40% and 50%, or by between about 50% and 60%.

Tobacco-specific nitrosamine (TSNA) content

In one embodiment the present invention provides a method of decreasing the content of at least one tobacco-specific nitrosamine (TSNA) precursor in a plant (e.g. a tobacco plant) or a part thereof or in a tobacco cell. Suitably, the method may comprise modifying said plant by modulating the activity or expression of at least one gene encoding an RNA binding protein. In one embodiment, the present invention provides a method of producing a processed leaf with decreased TSNA content (e.g. relative to a comparable product). The method of producing a processed leaf with decreased TSNA content may comprise:

modifying a plant by decreasing or inhibiting the activity or expression of at least one gene encoding an RNA binding protein;

harvesting a leaf from said plant;

and processing e.g. curing said harvested leaf.

The TSNA may be measured in a processed tobacco, e.g. cured tobacco or reconstituted tobacco. In one embodiment the TSNA content is measured and/or modified (e.g. reduced) in a cured tobacco plant or part thereof (e.g. in cured tobacco leaf).

The term“tobacco-specific nitrosamine” or“TSNA” as used herein has its usual meaning in the art, namely a nitrosamine which is found only in tobacco industry products or other nicotine- containing products. Suitably the at least one tobacco-specific nitrosamine may be N'- nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N'- nitrosoanatabine (NAT) or N-nitrosoanabasine (NAB).

The term“precursor thereto” when used in relation to at least one tobacco-specific nitrosamine refers to one or more chemicals or compounds of a tobacco plant that give rise to the formation of a tobacco-specific nitrosamine or are involved in the nitrosation reaction leading to tobacco- specific nitrosamine production.

In one embodiment the TSNA may be one or more of group selected from: N’-nitrosonornicotine (NNN), 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N’nitrosoanatabine (NAT) and N’-nitrosoanabasine (NAB). Suitably the at least one tobacco-specific nitrosamine may be NNK or NNN. In one embodiment the tobacco-specific nitrosamine is NNN. In another embodiment the tobacco-specific nitrosamine is NNK.

In one embodiment the precursor of the TSNA is one or more of the group selected from nornicotine, anabasine, anatabine, and an oxidised derivative of nicotine such as pseudooxynicotine (PON). In one embodiment the TSNA is N’nitrosonornicotine (NNN) and/or the precursor is nornicotine. In one embodiment the content of NNN is decreased. In one embodiment the content of nornicotine is decreased. In one embodiment the content of NNN and nornicotine is decreased. In one embodiment the TSNA is 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and/or the precursor is PON. In one embodiment the content of NNK is decreased. In one embodiment the content of PON is decreased. In one embodiment the content of NNK and PON is decreased.

In one embodiment the TSNA is N’nitrosoanatabine (NAT) and/or the precursor is anatabine. In one embodiment the content of NAT is decreased. In one embodiment the content of anatabine is decreased. In one embodiment the content of NAT and anatabine is decreased.

In one embodiment the TSNA is N’-nitrosoanabasine (NAB) and/or the precursor is anabasine.

In one embodiment the content of NAB is decreased. In one embodiment the content of nornicotine is decreased. In one embodiment the content of NAB and anabasine is decreased. The precursor of the TSNA (e.g. NNK, NNN, NAB and/or NAT) may be measured in green tobacco leaf, e.g. prior to processing, e.g. prior to curing. In one embodiment the precursor of the TSNA (e.g. NNK, NNN, NAB and/or NAT) is measured and/or modified (e.g. reduced) in a green tobacco leaf, e.g. prior to processing, e.g. prior to curing.

In one embodiment carrying out a method and or use of the invention results in a reduction of at least one TSNA or a precursor thereto in the modified tobacco plant (or part thereof) when compared to a tobacco plant (or part thereof) which has not been modified in accordance with the present invention.

The terms“reducing at least one TSNA or precursor thereto” or“reduction of at least one TSNA or precursor thereto” are used herein to mean that the concentration and/or total content of the at least one TSNA or precursor thereto in the product, method or use of the invention is lower in relation to a comparable product, method or use. For example, a comparable tobacco industry product would be derived from a tobacco plant which had not been modified according to the present invention, but in which all other relevant features were the same (e.g. plant species, growing conditions, method of processing tobacco, etc.).

Any method known in the art for determining the concentration and/or levels of at least one TSNA or precursor thereto may be used. In particular a method such may comprise the addition of deuterium labelled internal standard, an aqueous extraction and filtration, followed by analysis using reversed phase high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) may be used. Other examples for determining the concentration and/or level of a precursor to a tobacco-specific nitrosamine include a method such as the one detailed in CORESTA recommended method CRM-72: Determination of Tobacco Specific Nitrosamines in Tobacco and Tobacco Products by LC-MS/MS; CRM being developed into ISO/DIS 21766 or Wagner et al. (2005) Analytical Chemistry 77(4), 1001-1006 all of which are incorporated herein by reference.

Suitably the concentration and/or total content of the at least one tobacco-specific nitrosamine or precursor thereto may be reduced by carrying out a method and/or use of the present invention. Suitably the concentration and/or level of the at least one tobacco-specific nitrosamine or precursor thereto may be reduced in a tobacco plant of the invention (e.g. obtainable or obtained by a method and/or use of the invention) when compared to the concentration and/or level of the at least one tobacco-specific nitrosamine(s) or precursor thereto in a tobacco plant which has not been modified in accordance with present invention.

The concentration and/or total content of the at least one tobacco-specific nitrosamine(s) or precursor thereto may be reduced in a tobacco leaf, harvested leaf, processed tobacco leaf, tobacco industry product or combinations thereof obtainable or obtained from a tobacco plant (or part of a tobacco plant or a tobacco cell culture) of the invention when compared with a tobacco leaf, harvested leaf, processed tobacco leaf, tobacco industry product or combinations thereof obtainable or obtained from a tobacco plant (or part of a tobacco plant or a tobacco cell culture) which has not been modified in accordance with the present invention.

Suitably the concentration and/or total content of the at least one tobacco-specific nitrosamine or precursor thereto may be reduced in a processed tobacco leaf.

Suitably the concentration and/or level of the at least one tobacco-specific nitrosamine or precursor thereto may be reduced in a tobacco industry product.

In one embodiment the at least one tobacco-specific nitrosamine or precursor thereto may be reduced by at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40% or at least about 50%. In some embodiments the at least one tobacco-specific nitrosamine or precursor thereto may be reduced by between about 5% and about 50%, by between about 10% and about 50%, by between about 20% and about 50%, by between about 30% and about 50%, or by between about 40% and 50%.

In relation to processed (e.g. cured) tobacco leaf (e.g. cured or reconstituted), the at least one tobacco-specific nitrosamine or precursor thereto may be reduced by between about 5000 ng/g and about 50 ng/g, by between about 4000 ng/g and about 100 ng/g, by between about 3000 ng/g and 500 ng/g or by between 2000 ng/g and 1000 ng/g. In some embodiments the at least one tobacco-specific nitrosamine or precursor thereto may be reduced by at least about 5000 ng/g, at least about 4000 ng/g, at least about 3000 ng/g, at least about 2000 ng/g, at least about 1000 ng/g, at least about 500 ng/g, at least about 100 ng/g or at least about 50 ng/g. Biomass production

In some instances, it may be desirable to produce plants or biomass with high alkaloid levels e.g. high levels of nicotine content so that nicotine may be purified to produce a pure nicotine product for example for use in devices which utilize liquid containing nicotine (e.g. e-cigarettes) or within tobacco heating devices. For example, the production of nicotine in this way could reduce costs of nicotine extraction for the production of e-liquids for e-cigarettes.

In one aspect, the present invention provides a method of producing a biomass comprising: growing a cell which has been engineered to modulate (e.g. increase) the activity or expression of a gene encoding an RNA binding protein under conditions to produce a biomass. Suitably, the activity or expression of an RNA binding protein may be increased in order to increase the concentration and/or total nicotine content.

In one embodiment, the present invention provides a method of producing a biomass having modified (e.g. increased) concentration and/or total content of nicotine, comprising growing a cell which has been engineered to increase the activity or expression of at least one gene encoding an RNA binding protein comprising an amino acid sequence as set out in SEQ ID NO.

1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30, or a functional variant or functional fragment or orthologue of SEQ ID NO.

2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30.

The cell may be engineered by any method known in the art to modify the activity or expression of at least one gene encoding an RNA binding protein. Suitably, the cell may be engineered to express an exogenous gene encoding an RNA binding protein. Suitably, the cell may be engineered to overexpress a gene encoding an RNA binding protein.

Suitably, the biomass may contain a higher concentration and/or total content of nicotine compared with the biomass produced by a comparable cell which has not been modified in accordance with the present invention.

Suitably the cell for use in biomass production may be a plant cell, such as a tobacco cell.

Suitably the cell for use in biomass production may be a yeast cell.

In one embodiment the cell (e.g. yeast cell) may be further modified to comprise one or more sequences that increases nicotinic alkaloid biosynthesis. Suitably these one or more sequences may be incorporated into a nucleic acid construct that is suitable for cell (e.g. yeast cell) transformation. The one or more sequences may be overexpressed in the cell (e.g. yeast cell). The sequences may be selected from one or more of the following genes: MPO (or Methylputrescine Oxidase or MP01 or MP02); A622 (or Isoflavone reductase-like protein or Isoflavone reductase homolog or Isoflavone reductase-like protein); BBL (or Berberine bridge enzyme or Berberine bridge enzyme-like or BBE or NBB1); PMT (or Putrescine N- Methyltransferase or putrescine methyltransferase or S-adenosyl-L-methionine: putrescine N- methyltransferase or PMT or PMT1 or PMT2 or PMT3 or PMT4) and QPT (or quinolinate phosphoribosyltransferase). In one embodiment the sequences may be selected from one or more of the following genes: BBL, A622, PMT and MPO (MP01 or MP02). Genes suitable for modification in this way may be taught in US2016032299 for example, which is incorporated herein by reference.

Commercially desirable traits

In one embodiment the plants of the present invention have modified (i.e. increased or decreased) total alkaloid content and/or modified (i.e. increased or decreased) content of one or more alkaloids, whilst the flavour characteristics and/or other commercially desirable traits are at least maintained. Suitably, the plants of the present invention may have decreased total alkaloid content and/or decreased content of one or more alkaloids, whilst the flavour characteristics and/or other commercially desirable traits are at least maintained.

In one embodiment the plants of the present invention produce leaves of a similar grade and/or quality to plants which have not been modified according to the invention.

In one embodiment the plants of the present invention have reduced nornicotine and/or PON and/or anabasine and/or anatabine content without a significant change in the flavour characteristics of the plant (e.g. compared with the same plant which has not been modified in accordance with the present invention).

In one embodiment the plants of the present invention have decreased TSNA precursor content without a significant change (e.g. decrease) in other commercially desirable traits of the plant (e.g. compared with the same plant which has not been modified in accordance with the present invention). In particular the yield of the modified plant is preferably not reduced compared with the same plant which has not been modified in accordance with the present invention.

Therefore in one embodiment the methods and uses of the present invention relate to decreasing TSNA precursor content whilst maintaining the flavour characteristics and/or other commercially desirable traits (e.g. yield).

The term“commercially desirable traits” as used herein will include traits such as yield, mature plant height, harvestable leaf number, average node length, cutter leaf length, cutter leaf width, quality (e.g. leaf quality, suitably cured leaf quality), abiotic (for instance drought) stress tolerance, herbicide tolerance and/or biotic (for instance insect, bacteria or fungus) stress tolerance.

Leaf quality may be measured based on colour, texture and aroma of the cured leaf, for example according to United States Department of Agriculture (USDA) grades and standards. Tobacco grades are evaluated based on factors including, but not limited to, the leaf stalk position, leaf size, leaf colour, leaf uniformity and integrity, ripeness, texture, elasticity, sheen (related with the intensity and the depth of coloration of the leaf as well as the shine), hygroscopicity (the faculty of the tobacco leaves to absorb and to retain the ambient moisture), and green nuance or cast.

Leaf grade can be determined using standard methods known in the art, for example, using an Official Standard Grade published by the Agricultural Marketing Service of the US Department of Agriculture (7 U.S.C. §511 ). See, e.g., Official Standard Grades for Burley Tobacco (U.S. Type 31 and Foreign Type 93), effective November 5, 1990 (55 F.R. 40645); Official Standard Grades for Flue-Cured Tobacco (U.S. Types 11 , 12, 13, 14 and Foreign Type 92), effective March 27, 1989 (54 F.R. 7925); Official Standard Grades for Pennsylvania Seedleaf Tobacco (U.S. Type 41), effective January 8, 1965 (29 F.R. 16854); Official Standard Grades for Ohio Cigar-Leaf Tobacco (U.S. Types 42, 43, and 44), effective December 8, 1963 (28 F.R. 11719 and 28 F.R. 11926); Official Standard Grades for Wisconsin Cigar-Binder Tobacco (U.S. Types 54 and 55), effective November 20, 1969 (34 F.R. 17061); Official Standard Grades for Wsconsin Cigar-Binder Tobacco (U.S. Types 54 and 55), effective November 20, 1969 (34 F.R. 17061); Official Standard Grades for Georgia and Florida ShadeGrown Cigar-Wrapper Tobacco (U.S. Type 62), Effective April 1971. A USDA grade index value can be determined according to an industry accepted grade index. See e.g. Bowman et al. (1988) Tobacco Science, 32:39-40; Legacy Tobacco Document Library (Bates Document #523267826-523267833, July 1 , 1988, Memorandum on the Proposed Burley Tobacco Grade Index); and Miller et al. (1990) Tobacco Intern., 192:55-57 (all foregoing references are incorporated herein in their entirety).

In one aspect, a USDA grade index is a 0-100 numerical representation of federal grade received and is a weighted average of all stalk positions. A higher grade index indicates higher quality. Alternatively, leaf grade may be determined via hyper-spectral imaging. See e.g. WO 2011/027315 (which is incorporated herein by reference).

In one embodiment, a tobacco plant of the present invention provides tobacco of commercially acceptable grade.

Suitably, the tobacco plant of the present invention provides cured tobacco of commercially acceptable grade.

In one embodiment, a tobacco plant of the present invention is capable of producing leaves having a USDA grade index value of at least about 70% of the USDA grade index value of leaves of a comparable plant when grown in similar growth conditions. Suitably, tobacco plants disclosed herein may be capable of producing leaves having a USDA grade index value of at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the USDA grade index value of a control plant when grown in similar growth conditions. Suitably, tobacco plants disclosed herein may be capable of producing leaves having a USDA grade index value of between 65% and 130%, between 70% and 130%, between 75% and 130%, between 80% and 130%, between 85% and 130%, between 90% and 130%, between 95% and 130%, between 100% and 130%, between 105% and 130%, between 110% and 130%, between 115% and 130%, or between 120% and 130% of the USDA grade index value of a comparable plant.

In one aspect, the tobacco plant of the present invention is capable of producing leaves having a USDA grade index value of at least 50. Suitably, tobacco plants disclosed herein may be capable of producing leaves having a USDA grade index value of 55 or more, 60 or more, 65 or more, 70 or more, 75 or more, 80 or more, 85 or more, 90 or more, and 95 or more.

Unless specified otherwise, used herein, tobacco yield refers to cured leaf yield which is calculated based on the weight of cured tobacco leaves per acre under standard field conditions following standard agronomic and curing practice.

In one aspect, a plant (e.g. a tobacco plant) of the present invention has a yield between 50% and 150%, between 55% and 145%, between 60% and 140%, between 65% and 135%, between 70% and 130%, between 75% and 125%, between 80% and 120%, between 85% and 115%, between 90% and 110%, between 95% and 105%, between 50% and 100%, between 55% and 100%, between 60% and 100%, between 65% and 100%, between 70% and 100%, between 75% and 100%, between 80% and 100%, between 85% and 100%, between 90% and 100%, between 95% and 100%, between 100% and 150%, between 105% and 150%, between 110% and 150%, between 115% and 150%, between 120% and 150%, between 125% and 150%, between 130% and 150%, between 135% and 150%, between 140% and 150%, or between 145% and 150% of the yield of a comparable plant when grown in similar field conditions.

In another aspect, the plant (e.g. a tobacco plant) yield of the present invention is approximately 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0 times of the yield of a comparable plant when grown in similar field conditions.

In another aspect, the yield of a tobacco plant of the present invention is comparable to the yield of the flue cured comparable plant when grown in similar field conditions.

In one aspect, a tobacco plant of the present invention provides a yield selected from the group consisting of about between 1200 and 3500, between 1300 and 3400, between 1400 and 3300, between 1500 and 3200, between 1600 and 3100, between 1700 and 3000, between 1800 and 2900, between 1900 and 2800, between 2000 and 2700, between 2100 and 2600, between 2200 and 2500, and between 2300 and 2400 Ibs/acre.

In another aspect, a tobacco plant of the present invention provides a yield selected from the group consisting of about between 1200 and 3500, between 1300 and 3500, between 1400 and 3500, between 1500 and 3500, between 1600 and 3500, between 1700 and 3500, between 1800 and 3500, between 1900 and 3500, between 2000 and 3500, between 2100 and 3500, between 2200 and 3500, between 2300 and 3500, between 2400 and 3500, between 2500 and 3500, between 2600 and 3500, between 2700 and 3500, between 2800 and 3500, between 2900 and 3500, between 3000 and 3500, and between 3100 and 3500 Ibs/acre.

In a further aspect, a tobacco plant of the present invention provides a yield selected from the group consisting of about between 1200 and 3500, between 1200 and 3400, between 1200 and 3300, between 1200 and 3200, between 1200 and 3100, between 1200 and 3000, between 1200 and 2900, between 1200 and 2800, between 1200 and 2700, between 1200 and 2600, between 1200 and 2500, between 1200 and 2400, between 1200 and 2300, between 1200 and 2200, between 1200 and 2100, between 1200 and 2000, between 1200 and 1900, between 1200 and 1800, between 1200 and 1700, between 1200 and 1600, between 1200 and 1500, and between 1200 and 1400 Ibs/acre.

Plant breeding

In one embodiment the present invention provides a method of producing a plant having a modified alkaloid content and/or modified content of a tobacco specific nitrosamine (TSNA) precursor comprising:

a. crossing a donor plant having modified nicotine content and/or modified content of a tobacco specific nitrosamine (TSNA) precursor and wherein the activity or expression of at least one gene encoding an RNA binding protein according to the present invention has been modulated in the donor plant in accordance with the present invention with a recipient tobacco plant that does not have modified nicotine content or modified content of a tobacco specific nitrosamine (TSNA) precursor and possesses commercially desirable traits;

b. isolating genetic material from a progeny of said donor plant crossed with said recipient plant; and

c. performing molecular marker-assisted selection with a molecular marker comprising:

i. identifying an introgressed region comprising a mutation in a

polynucleotide sequence encoding a protein defined in a. Suitably, the activity or expression of a protein comprising an amino acid sequence as set out in SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30; or a protein encoded by a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8,

9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 is modulated in the donor plant when compared to a comparable plant. Suitably, the alkaloid content and/or TSNA precursor content is decreased by said method. Suitably, the alkaloid content and/or TSNA precursor content is decreased and the activity or expression of said RNA binding protein is decreased or inhibited.

The molecular marker assisted selection may comprise performing PCR to identify an introgressed nucleic acid sequence comprising a mutation which modulates the activity or expression of a protein comprising the amino acid sequence shown as SEQ ID NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28 or an amino acid sequence which has at least 80% identity thereto.

Plants

In one embodiment, the present invention relates to methods of modulating (e.g. decreasing) alkaloid content in plants, or parts thereof or plant cells.

Suitable plants according to the invention include the Solanaceae family of plants which include, for example jimson weed, eggplant, mandrake, deadly nightshade (belladonna), capsicum (paprika, chilli pepper), potato and tobacco.

In one embodiment a suitable genus of Solanaceae is Nicotiana, e.g. Nicotiana tabacum or Nicotiana rustica.

A suitable species of Nicotiana may be Nicotiana tabacum. Species of Nicotiana may be referred to herein as a tobacco plant, or simply tobacco.

Tobacco plants

The present invention provides methods, uses directed to plants (e.g. tobacco plants) as well as a cell (e.g. a tobacco cell), a plant (e.g. a tobacco plant) and a plant propagation material.

The term“tobacco plant” as used herein refers to a plant in the genus Nicotiana that is used in the production of tobacco industry products. Non-limiting examples of suitable“tobacco” plants include N. tabacum and N. rustica (for example, N. tabacum L, LA B21 , LN KY171 , Tl 1406, Basma, Galpao, Perique, Beinhart 1000-1 , and Petico). In one aspect, the tobacco plant according to the present invention is a non-naturally occurring tobacco plant. Suitably, the tobacco plant may be a mutant, non-naturally occurring tobacco plant. Suitably, the tobacco plant may be a transgenic tobacco plant.

In one aspect, the tobacco plant according to the present invention comprises a non-naturally occurring mutation which modulates (e.g. decreases) the activity or expression of at least one RNA binding protein as defined herein. Suitably, the tobacco plant may comprise a mutation which has been introduced.

The tobacco material can be derived or obtained from varieties of Nicotiana tabacum types, commonly known as Burley varieties, flue or bright varieties and dark varieties. In some embodiments, the tobacco material is derived from a Burley, Virginia or a dark tobacco plant. The tobacco plant may be selected from Burley tobacco, rare tobacco, speciality tobacco, expanded tobacco or the like.

The use of tobacco cultivars and elite tobacco cultivars is also contemplated herein. The tobacco plant for use herein may therefore be a tobacco variety or elite tobacco cultivar. Particularly useful Nicotiana tabacum varieties include Flue-cured Virginia type, Burley type, and Oriental type.

In some embodiments, the tobacco plant may be, for example, selected from one or more of the following varieties: L. cultivar T.l. 1068, AA 37-1 , B 13P, Xanthi (Mitchell-Mor), KT D#3 Hybrid 107, Bel-W3, 79-615, Samsun Holmes NN, F4 from cross BU21 x Hoja Parado, line 97, KTRDC#2 Hybrid 49, KTRDC#4 Hybrid 1 10, Burley 21 , PM016, KTRDC#5 KY 160 SI, KTRDC#7 FCA, KTRDC#6 TN 86 SI, PM021 , K 149, K 326, K 346, K 358, K 394, K 399, K 730, KY 10, KY 14, KY 160, KY 17, KY 8959, KY 9, KY 907, MD 609, McNair 373, NC 2000, PG 01 , PG 04, P01 , P02, P03, RG 11 , RG 17, RG 8, Speight G-28, TN 86, TN 90, VA 509, AS44, Banket A1 , Basma Drama B84/31 , Basma I Zichna ZP4/B, Basma Xanthi BX 2A, Batek, Besuki Jember, C104, Coker 319, Coker 347, Criollo Misionero, PM092, Delcrest, Djebel 81 , DVH 405, Galpao Comum, HB04P, Hicks Broadleaf, Kabakulak Elassona, PM102, Kutsage E1 , KY 14 x L8, KY 171 , LA BU 21 , McNair 944, NC 2326, NC 71 , NC 297, NC 3, PVH 03, PVH 09, PVH 19, PVH 21 10, Red Russian, Samsun, Saplak, Simmaba, Talgar 28, PM132, Wislica, Yayaldag, NC 4, TR Madole, Prilep HC-72, Prilep P23, Prilep PB 156/1 , Prilep P12-2/1 , Yaka JK-48, Yaka JB 125/3, TΊ-1068, KDH-960, TI-1070, TW136, PM204, PM205, Basma, TKF 4028, L8, TKF 2002, TN 90, GR141 , Basma xanthi, GR149, GR153, and Petit Havana.

Non-limiting examples of varieties or cultivars are: BD 64, CC 101 , CC 200, CC 27, CC 301 , CC 400, CC 500, CC 600, CC 700, CC 800, CC 900, Coker 176, Coker 319, Coker 371 Gold, Coker 48, CD 263, DF91 1 , DT 538 LC, Galpao tobacco, GL 26H, GL 350, GL 600, GL 737, GL 939, GL 973, HB 04P, HB 04P LC, HB3307PLC, Hybrid 403LC, Hybrid 404LC, Hybrid 501 LC, K 149, K 326, K 346, K 358, K394, K 399, K 730, KDH 959, KT 200, KT204LC, KY10, KY14, KY 160, KY 17, KY 171 , KU 907, KY907LC, KTY14xL8 LC, Little Crittenden, McNair 373, McNair 944, msKY 14xL8, Narrow Leaf Madole, Narrow Leaf Madole LC, NBH 98, N-126, N-777LC, N- 7371 LC, NC 100, NC 102, NC 2000, NC 291 , NC 297, NC 299, NC 3, NC 4, NC 5, NC 6, NC7, NC 606, NC 71 , NC 72, NC 810, NC BH 129, NC 2002, Neal Smith Madole, OXFORD 207, PD 7302 LC, PD 7309 LC, PD 7312 LC 'Periq'e' tobacco, PVH03, PVH09, PVH19, PVH50, PVH51 , R 610, R 630, R 7-1 1 , R 7-12, RG 17, RG 81 , RG H51 , RGH 4, RGH 51 , RS 1410, Speight 168, Speight 172, Speight 179, Speight 210, Speight 220, Speight 225, Speight 227, Speight 234, Speight G-28, Speight G-70, Speight H-6, Speight H20, Speight NF3, Tl 1406, Tl 1269, TN 86, TN86LC, TN 90, TN 97, TN97LC, TN D94, TN D950, TR (Tom Rosson) Madole, VA 309, VA359, AA 37-1 , B 13P, Xanthi (Mitchell-Mor), Bel-W3, 79-615, Samsun Holmes NN, KTRDC number 2 Hybrid 49, Burley 21 , KY 8959, KY 9, MD 609, PG 01 , PG 04, P01 , P02, P03, RG 1 1 , RG 8, VA 509, AS44, Banket A1 , Basma Drama B84/31 , Basma I Zichna ZP4/B, Basma Xanthi BX 2A, Batek, Besuki Jember, C104, Coker 347, Criollo Misionero, Delcrest, Djebel 81 , DVH 405, Galpao Comum, HB04P, Hicks Broadleaf, Kabakulak Elassona, Kutsage E1 , LA BU 21 , NC 2326, NC 297, PVH 21 10, Red Russian, Samsun, Saplak, Simmaba, Talgar 28, Wislica, Yayaldag, Prilep HC-72, Prilep P23, Prilep PB 156/1 , Prilep P12-2/1 , Yaka JK-48, Yaka JB 125/3, TI-1068, KDH-960, TI-1070, TW136, Basma, TKF 4028, L8, TKF 2002, GR141 , Basma xanthi, GR149, GR153, Petit Havana. Low converter subvarieties of the above, even if not specifically identified herein, are also contemplated.

The tobacco plant may be a Burley, Flue-cured Virginia, or Oriental.

In one embodiment the plant propagation material may be obtainable from a plant (e.g. a tobacco plant) of the invention.

A“plant propagation material” as used herein refers to any plant matter taken from a plant from which further plants may be produced. Suitably, a plant propagation material may be selected from a seed, plant calli and plant clumps. Suitably the plant propagation material may be a seed. Suitably, the plant propagation material may be plant calli. Suitably the plant propagation material may be plant clumps.

In one embodiment the cell (e.g. tobacco cell), tobacco plant and/or plant propagation material may be obtainable (e.g. obtained) by a method according to the invention.

Suitably a tobacco plant according to the present invention may have modulated (e.g. decreased) nicotine content when compared to an unmodified tobacco plant, wherein the tobacco plant has been modified to modulate (e.g. decrease) the activity or expression of at least on one gene encoding an RNA binding protein. Suitably a tobacco plant according to the present invention may have decreased nicotine content when compared to an unmodified tobacco plant, wherein the tobacco plant has been modified to decrease or inhibit the activity or expression of at least on one gene encoding an RNA binding protein. Suitably a tobacco plant according to the present invention may have modulated (e.g. reduced) content of a tobacco specific nitrosamine (TSNA) precursor when compared to an unmodified tobacco plant, wherein the tobacco plant has been modified to modulate (e.g. increase) the activity or expression of at least on one gene encoding an RNA binding protein.

Suitably a tobacco plant according to the present invention may have decreased tobacco specific nitrosamine (TSNA) precursor content when compared to an unmodified tobacco plant, wherein the tobacco plant has been modified to decrease or inhibit the activity or expression of at least on one gene encoding an RNA binding protein.

In one embodiment the tobacco plant in accordance with the present invention comprises a tobacco cell of the invention.

In another embodiment the plant propagation material may be obtainable (e.g. obtained) from a tobacco plant of the invention.

In one embodiment there is provided the use of a tobacco plant as described herein to breed a tobacco plant.

The present invention also provides in another embodiment the use of a tobacco plant of the foregoing embodiments for the production of a tobacco industry product.

In another embodiment there is provided the use of a tobacco plant of the invention to grow a crop.

In one embodiment there is provided a cell such as a plant cell, such as a tobacco plant cell having modulated activity or expression of at least one gene encoding an RNA binding protein as defined herein. Suitably, the cell may be a non-naturally occurring cell. Suitably, the cell may be a mutant cell. Suitably, the cell may be a non-naturally occurring mutant cell. For example the cell may comprise a non-naturally occurring mutation which modulates (e.g. decreases) activity or expression of at least one gene encoding an RNA binding protein as defined herein.

In one embodiment there is provided the use of a cell as provided for in the foregoing embodiments for production of a tobacco industry product.

In one embodiment the present invention provides a cell culture (e.g. in in vitro culture).

The tobacco cell culture may be a cell suspension culture. These cells cultured in vitro may be incorporated into a tobacco industry product, e.g. as a substitute for conventional tobacco particles, shreds, fine cut or long cut tobacco lamina, as an additive ingredient or as both a substitute and an additive. Suitably, the cell culture may produce nicotine.

In one embodiment there is provided the use of a cell culture, e.g. a harvested and/or processed cell culture according to the present invention for the production of a tobacco industry product. The tobacco cells harvested from an in vitro culture may be dried, e.g. freeze-dried, for example to produce a powder. In one embodiment, the cell culture is a tobacco cell culture. The skilled person will be aware of known methods for establishing in vitro cultures of tobacco cells. By way of example only, the following method may be used: collecting seeds form a tobacco plant of interest and sterilising their exterior to eliminate unwanted organisms, planting said seeds to grown a tobacco plant of interest, removing tissue from the tobacco plant (for example, from the tobacco stem) for use as an explant, establishing a callus culture form the tobacco explant, establishing a cell suspension culture from the callus culture, and harvesting culture material (e.g. including tobacco cells) to produce a tobacco cell culture.

The tobacco cells can be harvested by various methods, including filtration, e.g. vacuum filtration. The sample may be washed in the filter by adding water and the remaining liquid removed with the filtration, e.g. vacuum filtration.

The harvested tobacco cell culture may be further processed, e.g. dried, such as air-dried and/or freeze-dried. The harvested tobacco cell culture or dried harvested tobacco cell culture or an extract therefrom may be incorporated into tobacco industry products according to the present invention.

In one embodiment, the present invention provides a plant (e.g. tobacco plant) or part thereof for use in molecular farming. Suitably, a plant or part thereof modified in accordance with the present invention may be used in the manufacture of proteins such as therapeutics e.g. antibiotics, virus like particles, neutraceuticals or small molecules.

In one embodiment, the present invention provides a method for the production of proteins (e.g. therapeutic proteins), the method comprising modifying a plant or part thereof capable of producing said protein (e.g. therapeutic protein) by modulating the activity or expression of at least one gene encoding an RNA binding protein having an amino acid sequence as set out in SEQ I D NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28 or a functional variant or functional fragment or orthologue thereof, or a sequence which has at least 80% identity to SEQ I D NO. 1 , 4, 7, 10, 13, 16, 19, 22, 25 or 28; or wherein the at least one gene encoding an RNA binding protein comprises a nucleotide sequence as set out in SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a functional variant or functional fragment or orthologue of SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30 or a nucleic acid sequence which has at least 80% identity to SEQ ID NO. 2, 3, 5, 6, 8, 9, 11 , 12, 14, 15, 17, 18, 20, 21 , 23, 24, 26, 27, 29 or 30; and culturing the plant under conditions sufficient to allow the production of said protein (e.g. therapeutic protein). Products

The present invention also provides for products obtainable or obtained from plants according to the present invention. Products are provided which are obtainable or obtained from a plant in which the activity or expression of gene encoding an RNA binding protein has been modulated. In one embodiment, the product may comprise a construct of the invention which modulates the activity or expression of at least one gene encoding an RNA binding protein as defined herein. In one embodiment, the product may comprise a construct of the invention which modifies the nucleic acid sequence of at least one gene encoding an RNA binding protein as defined herein. The present invention also provides for products obtainable or obtained from tobacco according to the present invention.

In one embodiment there is provided the use of a tobacco plant of the invention to produce a tobacco leaf.

Suitably the tobacco leaf may be subjected to downstream applications such as processing. Thus in one embodiment the use of the foregoing embodiment may provide a processed tobacco leaf. Suitably the tobacco leaf may be subjected to curing, fermenting, pasteurising or combinations thereof. In another embodiment the tobacco leaf may be cut. In some embodiments the tobacco leaf may be cut before or after being subjected to curing, fermenting, pasteurising or combinations thereof.

In one embodiment the present invention provides a harvested leaf of a tobacco plant of the invention.

In a further embodiment the harvested leaf may be obtainable (e.g. obtained) from a tobacco plant propagated from a propagation material of the present invention.

In another embodiment there is provided a harvest leaf obtainable from a method or use of the present invention.

Suitably the harvested leaf may be a cut harvested leaf.

In some embodiments the harvested leaf may comprise viable tobacco cells. In other embodiments the harvested leaf may be subjected to further processing.

There is also provided a processed tobacco leaf.

The processed tobacco leaf may be obtainable from a tobacco plant of the invention. Suitably the processed tobacco leaf may be obtainable from a tobacco plant obtained in accordance with any of the methods and/or uses of the present invention.

Suitably, the processed leaf may comprise reduced content of one or more TSNAs selected from NNN, NNK, NAT and NAB. Suitably, the content of NNN may be reduced. Preferably, the content of NNK may be reduced. Suitably, the content of NAT may be reduced. Suitably, the content of NAB may be reduced. Suitably, the reduction in TSNA content is in relation to a comparable product which has not been modified according to the present invention. In another embodiment the processed tobacco leaf may be obtainable (e.g. obtained) from a tobacco plant propagated form a tobacco plant propagation material according to the present invention.

The processed tobacco leaf of the present invention may be obtainable (e.g. obtained) by processing a harvested leaf of the invention.

The term“processed tobacco leaf” as used herein refers to a tobacco leaf that has undergone one or more processing steps to which tobacco is subjected to in the art. A“processed tobacco leaf’ comprises no or substantially no viable cells.

The term“viable cells” refers to cells which are able to grow and/or are metabolically active. Thus, if a cell is said to not be viable, also referred to as“non-viable” then a cell does not display the characteristics of a viable cell.

The term“substantially no viable cells” means that less than about 5% of the total cells are viable. Preferably, less than about 3%, more preferably less than about 1 %, even more preferably less than about 0.1% of the total cells are viable.

In one embodiment the processed tobacco leaf may be processed by one or more of: curing, fermenting and/or pasteurising.

Suitably the processed tobacco leaf may be processed by curing.

Tobacco leaf may be cured by any method known in the art. In one embodiment tobacco leaf may be cured by one or more of the curing methods selected from the group consisting of: air curing, fire curing, flue curing and sun curing.

Suitably the tobacco leaf may be air cured.

Typically air curing is achieved by hanging tobacco leaf in well-ventilated barns and allowing to dry. This is usually carried out over a period of four to eight weeks. Air curing is especially suitable for burley tobacco.

Suitably the tobacco leaf may be fire cured. Fire curing is typically achieved by hanging tobacco leaf in large barns where fires of hardwoods are kept on continuous or intermittent low smoulder and usually takes between three days and ten weeks, depending on the process and the tobacco.

In another embodiment the tobacco leaf may be flue cured. Flue curing may comprise stringing tobacco leaves onto tobacco sticks and hanging them from tier-poles in curing barns. The barns usually have a flue which runs from externally fed fire boxes. Typically this results in tobacco that has been heat-cured without being exposed to smoke. Usually the temperature will be raised slowly over the course of the curing with the whole process taking approximately 1 week.

Suitably the tobacco leaf may be sun cured. This method typically involves exposure of uncovered tobacco to the sun. Suitably the processed tobacco leaf may be processed by fermenting.

Fermentation can be carried out in any manner known in the art. Typically during fermentation, the tobacco leaves are piled into stacks (a bulk) of cured tobacco covered in e.g. burlap to retain moisture. The combination of the remaining water inside the leaf and the weight of the tobacco generates a natural heat which ripens the tobacco. The temperature in the centre of the bulk is monitored daily. In some methods every week, the entire bulk is opened. The leaves are then removed to be shaken and moistened and the bulk is rotated so that the inside leaves go outside and the bottom leaves are placed on the top of the bulk. This ensures even fermentation throughout the bulk. The additional moisture on the leaves, plus the actual rotation of the leaves themselves, generates heat, releasing the tobacco’s natural ammonia and reducing nicotine, while also deepening the colour and improving the tobacco’s aroma. Typically the fermentation process continues for up to 6 months, depending on the variety of tobacco, stalk position on the leaf, thickness and intended use of leaf.

Suitably the processed tobacco leaf may be processed by pasteurising. Pasteurising may be particularly preferred when the tobacco leaf will be used to make a smokeless tobacco industry product, most preferably snus.

Tobacco leaf pasteurisation may be carried out by any method known in the art. For example pasteurisation may be carried out as detailed in J Foulds, L Ramstrom, M Burke, K Fagerstrom. Effect of smokeless tobacco (snus) on smoking and public health in Sweden Tobacco Control (2003) 12: 349-359, the teaching of which is incorporated herein by reference.

During the production of snus, pasteurisation is typically carried out by a process in which the tobacco is heat treated with steam for 24-36 hours (reaching temperatures of approximately 100°C). This results in an almost sterile product and without wishing to be bound by theory one of the consequences of this is believed to be a limitation of further TSNA formation.

In one embodiment the pasteurisation may be steam pasteurisation.

In some embodiments the processed tobacco leaf may be cut. The processed tobacco leaf may be cut before or after processing. Suitably, the processed tobacco leaf may be cut after processing.

In one embodiment, the use of the foregoing embodiment may provide reconstituted tobacco.

In one embodiment, there is provided reconstituted tobacco.

“Reconstituted” as used herein may also be referred to as recon, recycled or homogenized sheet tobacco and refers to tobacco material generated from remnants of tobacco leaf after processing. Reconstituted tobacco allows the production of a consistent, high quality blend and allows the adjustment of the ratio of individual components.

Reconstituted tobacco may be nano fibre recon (nanofibers can be extracted in solid or liquid form), paper making recon (which uses stems, scraps, and midribs, etc. as the raw material) or slurry type recon (which uses a mixture of fines and tobacco stems, ground to power, mixed with water and vegetable binding agent; the soluble residue is formed to sheets by extracting the water).

Any method known in the art may be used for making reconstituted tobacco, for example see CORESTA Congress, Sapporo, 2012, Smoke Science/Product Technology Groups, SSPT 12 (incorporated herein by reference).

In some embodiments the tobacco plant, harvested leaf of a tobacco plant and/or processed tobacco leaf may be used to extract nicotine. The extraction of nicotine can be achieved using any method known in the art. For example a method for extracting nicotine from tobacco is taught in US 2,162,738 which is incorporated herein by reference.

In one aspect, the present invention provides cured tobacco material made from a tobacco plant or part thereof according to the invention.

Suitably, the cured tobacco may comprise a reduced content of one or more TSNAs selected from NNK, NNN, NAT and NAB. Suitably, the content of NNN may be reduced. Preferably, the content of NNK may be reduced. Suitably, the content of NAT may be reduced. Suitably, the content of NAB may be reduced. Suitably, the reduction in TSNA content is in relation to a comparable product which has not been modified according to the present invention.

In another aspect, the present invention provides a tobacco blend comprising tobacco material made from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. In one aspect, the present invention provides a tobacco blend comprising cured tobacco material according to the present invention.

Suitably, the tobacco blend according to the present invention may comprise approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 10% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 20% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 30% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 40% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 50% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 60% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 70% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 80% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 90% tobacco from a tobacco plant or part thereof according to the present invention, or from a tobacco cell culture according to the present invention.

In one aspect, a tobacco blend product of the present invention comprises at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95 percent by dry weight of tobacco cured from a tobacco plant or part thereof according to the present invention, or a tobacco cell culture according to the present invention.

Suitably, the cured tobacco material may be air cured. Suitably, the cured tobacco material may be flue cured. Suitably, the cured tobacco material may be sun cured. Suitably, the cured tobacco material may be fire cured.

A tobacco industry product or smoking article according to the present invention may comprise the tobacco material (e.g. cured tobacco material or reconstituted tobacco material) according to the present invention.

In another aspect the present invention provides a tobacco industry product.

In one embodiment the tobacco industry product according to the present invention may be a blended tobacco industry product. Suitably, the tobacco blend may comprise cured tobacco material according to the present invention.

In one embodiment the tobacco industry product may be prepared from a tobacco plant of the invention or a part thereof.

Suitably the tobacco plant or part thereof may be propagated from a tobacco plant propagation material according to the present invention.

The term“part thereof” as used herein in the context of a tobacco plant refers to a portion of the tobacco plant. Suitably, the“part thereof” may be a leaf, root or stem of a tobacco plant or the flowers. Suitably, the“part thereof” may be a leaf, root or stem of a tobacco plant.

Delivery system

As used herein, the term“delivery system” is intended to encompass systems that deliver at least one substance to a user, and includes:

combustible aerosol provision systems, such as cigarettes, cigarillos, cigars, and tobacco for pipes or for roll-your-own or for make-your-own cigarettes (whether based on tobacco, tobacco derivatives, expanded tobacco, reconstituted tobacco, tobacco substitutes or other smokable material);

non-combustible aerosol provision systems that release compounds from an aerosol generating material without combusting the aerosol-generating material, such as electronic cigarettes, tobacco heating products, and hybrid systems to generate aerosol using a combination of aerosol-generating materials; and

aerosol-free delivery systems that deliver the at least one substance to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products such as oral tobacco which includes snus or moist snuff, wherein the at least one substance may or may not comprise nicotine.

According to the present disclosure, a“combustible” aerosol provision system is one where a constituent aerosol-generating material of the aerosol provision system (or component thereof) is combusted or burned during use in order to facilitate delivery of at least one substance to a user.

In some embodiments, the delivery system is a combustible aerosol provision system, such as a system selected from the group consisting of a cigarette, a cigarillo and a cigar.

In some embodiments, the disclosure relates to a component for use in a combustible aerosol provision system, such as a filter, a filter rod, a filter segment, a tobacco rod, a spill, an aerosol-modifying agent release component such as a capsule, a thread, or a bead, or a paper such as a plug wrap, a tipping paper or a cigarette paper.

According to the present disclosure, a“non-combustible” aerosol provision system is one where a constituent aerosol-generating material of the aerosol provision system (or component thereof) is not combusted or burned in order to facilitate delivery of at least one substance to a user.

In some embodiments, the delivery system is a non-combustible aerosol provision system, such as a powered non-combustible aerosol provision system.

In some embodiments, the non-combustible aerosol provision system is an electronic cigarette, also known as a vaping device or electronic nicotine delivery system (END), although it is noted that the presence of nicotine in the aerosol-generating material is not a requirement.

In some embodiments, the non-combustible aerosol provision system is an aerosol generating material heating system, also known as a heat-not-burn system. An example of such a system is a tobacco heating system.

In some embodiments, the non-combustible aerosol provision system is a hybrid system to generate aerosol using a combination of aerosol-generating materials, one or a plurality of which may be heated. Each of the aerosol-generating materials may be, for example, in the form of a solid, liquid or gel and may or may not contain nicotine. In some embodiments, the hybrid system comprises a liquid or gel aerosol-generating material and a solid aerosol-generating material. The solid aerosol-generating material may comprise, for example, tobacco or a non-tobacco product.

Typically, the non-combustible aerosol provision system may comprise a non-combustible aerosol provision device and a consumable for use with the non-combustible aerosol provision device.

In some embodiments, the disclosure relates to consumables comprising aerosol generating material and configured to be used with non-combustible aerosol provision devices. These consumables are sometimes referred to as articles throughout the disclosure.

In some embodiments, the non-combustible aerosol provision system, such as a non combustible aerosol provision device thereof, may comprise a power source and a controller. The power source may, for example, be an electric power source or an exothermic power source. In some embodiments, the exothermic power source comprises a carbon substrate which may be energised so as to distribute power in the form of heat to an aerosol-generating material or to a heat transfer material in proximity to the exothermic power source.

In some embodiments, the non-combustible aerosol provision system may comprise an area for receiving the consumable, an aerosol generator, an aerosol generation area, a housing, a mouthpiece, a filter and/or an aerosol-modifying agent.

In some embodiments, the consumable for use with the non-combustible aerosol provision device may comprise aerosol-generating material, an aerosol-generating material storage area, an aerosol-generating material transfer component, an aerosol generator, an aerosol generation area, a housing, a wrapper, a filter, a mouthpiece, and/or an aerosol-modifying agent.

Suitably, the delivery system may be prepared from (e.g. may comprise) a tobacco plant or a part thereof according to the present invention.

Suitably, the delivery system may be prepared from a tobacco cell culture according to the present invention.

Suitably, the delivery system may be prepared from (e.g. may comprise) a tobacco plant or part thereof propagated from a tobacco plant propagation material according to the present invention.

Suitably, the delivery system may be prepared from (e.g. may comprise) a harvested leaf of a tobacco plant according to the present invention. Suitably, the delivery system may be prepared from (e.g. may comprise) a processed tobacco leaf according to the present invention.

Suitably, the delivery system may be prepared from (e.g. may comprise) a cured tobacco material according to the present invention.

Suitably, the delivery system may be prepared from (e.g. may comprise) a tobacco blend according to the present invention.

In one embodiment, the delivery system is a combustible smoking article, selected from the group consisting of a cigarette, a cigarillo and a cigar.

In one embodiment, the delivery system comprises one or more components of a combustible smoking article, such as a filter, a filter rod, a filter rod segments, tobacco, a tobacco rod, a tobacco rod segment, a spill, an additive release component such as a capsule, a thread, beads, a paper such as a plug wrap, a tipping paper or a cigarette paper.

In one embodiment, the delivery system is a non-combustible aerosol provision system.

In one embodiment, the delivery system comprises one or more components of a non combustible aerosol provision system, such as a heater and an aerosolizable substrate.

In one embodiment, the aerosol provision system is an electronic cigarette also known as a vaping device.

In one embodiment the electronic cigarette comprises a heater, a power supply capable of supplying power to the heater, an aerosolizable substrate such as a liquid or gel, a housing and optionally a mouthpiece.

In one embodiment the aerosolizable substrate is contained in a substrate container. In one embodiment the substrate container is combined with or comprises the heater.

In one embodiment, the delivery system is a heating product which releases one or more compounds by heating, but not burning, a substrate material. The substrate material is an aerosolizable material which may be for example tobacco or other non-delivery systems, which may or may not contain nicotine. In one embodiment, the heating product is a tobacco heating product.

In one embodiment, the heating product is an electronic device.

In one embodiment, the tobacco heating product comprises a heater, a power supply capable of supplying power to the heater, an aerosolizable substrate such as a solid or gel material.

In one embodiment the heating product is a non-electronic article.

In one embodiment the heating product comprises an aerosolizable substrate such as a solid or gel material and a heat source which is capable of supplying heat energy to the

aerosolizable substrate without any electronic means, such as by burning a combustion material, such as charcoal.

In one embodiment the heating product also comprises a filter capable of filtering the aerosol generated by heating the aerosolizable substrate.

In some embodiments the aerosolizable substrate material may comprise a vapour or aerosol generating agent or a humectant, such as glycerol, propylene glycol, triacetin or diethylene glycol.

In one embodiment, the delivery system is a hybrid system to generate aerosol by heating, but not burning, a combination of substrate materials. The substrate materials may comprise for example solid, liquid or gel which may or may not contain nicotine. In one embodiment, the hybrid system comprises a liquid or gel substrate and a solid substrate. The solid substrate may be for example tobacco or other non-delivery systems, which may or may not contain nicotine. In one embodiment, the hybrid system comprises a liquid or gel substrate and tobacco. In another embodiment, the product may comprise a construct of the invention which modulates activity or expression of at least one RNA binding domain containing protein and thereby decreases alkaloid content when expressed in a plant (e.g. tobacco plant).

Tobacco industry product

As used herein, the term “tobacco industry product” is intended to include combustible smoking articles such as cigarettes, cigarillos, cigars, tobacco for pipes or for roll-your-own cigarettes, (whether based on tobacco, tobacco derivatives, expanded tobacco, reconstituted tobacco, tobacco substitutes or other smokable material), non-combustible aerosol provision systems such as heating products that release compounds from substrate materials without burning such as electronic cigarettes, tobacco heating products, and hybrid systems to generate aerosol from a combination of substrate materials, for example hybrid systems containing a liquid or gel or solid substrate, as well as aerosolizable substrate materials used within these aerosol provision systems; and aerosol-free delivery articles such as lozenges, gums, patches, articles comprising breathable powders and smokeless tobacco industry products such as snus and snuff, which aerosol-free delivery articles may or may not deliver nicotine.

In one embodiment the tobacco industry product may be prepared from (e.g. may comprise) a tobacco plant of the invention or a part thereof.

Suitably the tobacco plant or part thereof may be propagated from a tobacco plant propagation material according to the present invention.

The term“part thereof” as used herein in the context of a tobacco plant refers to a portion of the tobacco plant. Preferably the“part thereof” is a leaf of a tobacco plant.

In another embodiment the tobacco industry product may be prepared from a harvested leaf of the invention. In a further embodiment the tobacco industry product may be prepared from a processed tobacco leaf of the invention.

Suitably the tobacco industry product may be prepared from a tobacco leaf processed by one or more of: curing, fermenting and/or pasteurising.

Suitably the tobacco industry product may comprise a cut tobacco leaf, optionally processed as per the foregoing embodiment.

In another embodiment, the tobacco industry product may be prepared from a tobacco cell culture according to the present invention.

In another embodiment, the tobacco industry product may be prepared from (e.g. may comprise) a cured tobacco material according to the present invention.

In another embodiment, the tobacco industry product may be prepared from (e.g. may comprise) a tobacco blend according to the present invention.

In one embodiment the tobacco industry product may be a smoking article.

As used herein, the term“smoking article” can include smokeable products, such as rolling tobacco, cigarettes, cigars and cigarillos whether based on tobacco, tobacco derivatives, expanded tobacco, reconstituted tobacco or tobacco substitutes.

In another embodiment the tobacco industry product may be a smokeless tobacco industry product.

The term“smokeless tobacco industry product” as used herein refers to a tobacco industry product that is not intended to be smoked and/or subjected to combustion.

Smokeless tobacco industry products (including heat-not-burn materials) may contain tobacco in any form, including dried particles, shreds, granules, powders, or slurry, deposited on, mixed in, surrounded by, or combined with other ingredients in any format, such as flakes, films, tabs, foams, or beads.

In one embodiment a smokeless tobacco industry product may include snus, snuff, chewing tobacco or the like.

In one embodiment, the tobacco industry product is a combustible smoking article, selected from the group consisting of a cigarette, a cigarillo and a cigar.

In one embodiment, the tobacco industry product comprises one or more components of a combustible smoking article, such as a filter, a filter rod, a filter rod segments, tobacco, a tobacco rod, a tobacco rod segment, a spill, an additive release component such as a capsule, a thread, beads, a paper such as a plug wrap, a tipping paper or a cigarette paper.

In one embodiment, the tobacco industry product is a non-combustible aerosol provision system.

In one embodiment, the tobacco industry product comprises one or more components of a non-combustible aerosol provision system, such as a heater and an aerosolizable substrate. In one embodiment, the aerosol provision system is an electronic cigarette also known as a vaping device.

In one embodiment the electronic cigarette comprises a heater, a power supply capable of supplying power to the heater, an aerosolizable substrate such as a liquid or gel, a housing and optionally a mouthpiece.

In one embodiment the aerosolizable substrate is contained in a substrate container. In one embodiment the substrate container is combined with or comprises the heater.

In one embodiment, the tobacco industry product is a heating product which releases one or more compounds by heating, but not burning, a substrate material. The substrate material is an aerosolizable material which may be for example tobacco or other non-tobacco products, which may or may not contain nicotine. In one embodiment, the heating product is a tobacco heating product.

In one embodiment, the heating product is an electronic device.

In one embodiment, the tobacco heating product comprises a heater, a power supply capable of supplying power to the heater, an aerosolizable substrate such as a solid or gel material.

In one embodiment the heating product is a non-electronic article.

In one embodiment the heating product comprises an aerosolizable substrate such as a solid or gel material and a heat source which is capable of supplying heat energy to the

aerosolizable substrate without any electronic means, such as by burning a combustion material, such as charcoal.

In one embodiment the heating product also comprises a filter capable of filtering the aerosol generated by heating the aerosolizable substrate.

In some embodiments the aerosolizable substrate material may comprise a vapour or aerosol generating agent or a humectant, such as glycerol, propylene glycol, triacetin or diethylene glycol.

In one embodiment, the tobacco industry product is a hybrid system to generate aerosol by heating, but not burning, a combination of substrate materials. The substrate materials may comprise for example solid, liquid or gel which may or may not contain nicotine. In one embodiment, the hybrid system comprises a liquid or gel substrate and a solid substrate. The solid substrate may be for example tobacco or other non-tobacco products, which may or may not contain nicotine. In one embodiment, the hybrid system comprises a liquid or gel substrate and tobacco.

In a further embodiment the tobacco industry product may be a tobacco heating device or hybrid device or e-cigarette or the like.

Typically in tobacco heating devices or hybrid devices, an aerosol is generated by the transfer of heat from a heat source to a physically separate aerosol-forming substrate or material, which may be located within, around or downstream of the heat source. During smoking, volatile compounds are released from the aerosol-forming substrate by heat transfer from the heat source and entrained in air drawn through the smoking article. As the released compounds cool, they condense to form an aerosol that is inhaled by the user.

Aerosol-generating articles and devices for consuming or smoking tobacco heating devices are known in the art. They can include, for example, electrically heated aerosol-generating devices in which an aerosol is generated by the transfer of heat from one or more electrical heating elements of the aerosol-generating device to the aerosol-forming substrate of a tobacco heating device.

Suitably the tobacco heating device may be an aerosol-generating device.

Preferably the tobacco heating device may be a heat-not-burn device. Heat-not-burn devices are known in the art and release compounds by heating, but not burning, tobacco.

An example of a suitable, heat-not-burn device may be one taught in WO2013/034459 or GB2515502 which are incorporated herein by reference.

In one embodiment the aerosol-forming substrate of a tobacco heating device may be a tobacco industry product in accordance with the present invention.

In one embodiment the tobacco heating device may be a hybrid device.

Polvnucleotides/polvpeptides/constructs

In certain embodiments of the present invention, constructs which modulate activity or expression at least gene encoding an RNA binding protein as described herein may be transformed into plant cells, suitably under the direction of a promoter.

In certain embodiments of the present invention, constructs which decrease (i.e. inhibit) the activity or expression of at least one gene encoding an RNA binding protein as described herein may be transformed into plant cells under the direction of a promoter. For example, the genetic construct may be a gene editing construct or may comprise an RNAi molecule, which may comprise a small interfering RNA (siRNA) molecule, or a short hairpin loop (shRNA) molecule.

In certain embodiments of the present invention, constructs which increase activity or expression of gene encoding an RNA binding protein as described herein may be transformed into plant cells, suitably under the direction of a promoter e.g. constructs which encode a gene encoding an RNA binding protein such as an endogenous RNA binding protein.

Constructs may be introduced into plants according to the present invention by means of suitable vector, e.g. plant transformation vectors. A plant transformation vector may comprise an expression cassette comprising 5'-3' in the direction of transcription, a promoter sequence, a construct sequence targeting gene encoding an RNA binding protein as described herein and, optionally a 3' untranslated, terminator sequence including a stop signal for RNA polymerase and a polyadenylation signal for polyadenylase. The promoter sequence may be present in one or more copies, and such copies may be identical or variants of a promoter sequence as described above. The terminator sequence may be obtained from plant, bacterial or viral genes. Suitable terminator sequences are the pea rbcS E9 terminator sequence, the nos terminator sequence derived from the nopaline synthase gene of Agrobacterium tumefaciens and the 35S terminator sequence from cauliflower mosaic virus, for example. A person skilled in the art will be readily aware of other suitable terminator sequences.

The construct of the present invention may also comprise a gene expression enhancing mechanism to increase the strength of the promoter. An example of such an enhancer element is one derived from a portion of the promoter of the pea plastocyanin gene, and which is the subject of International Patent Application NO. NO. WO 97/20056 which is incorporated herein by reference. Suitable enhancer elements may be the nos enhancer element derived from the nopaline synthase gene of Agrobacterium tumefaciens and the 35S enhancer element from cauliflower mosaic virus, for example.

These regulatory regions may be derived from the same gene as the promoter DNA sequence or may be derived from different genes, from Nicotiana tabacum or other organisms, for example from a plant of the family Solanaceae, or from the subfamily Cestroideae. All of the regulatory regions should be capable of operating in cells of the tissue to be transformed.

The promoter DNA sequence may be derived from the same gene as the gene of interest, e.g. the gene the promoter is going to direct, for instance a gene encoding an RNA binding protein according to the invention, a coding sequence used in the present invention or may be derived from a different gene, from Nicotiana tabacum, or another organism, for example from a plant of the family Solanaceae, or from the subfamily Cestroideae.

The expression cassette may be incorporated into a basic plant transformation vector, such as pBIN 19 Plus, pBI 101, pKYLX71 :35S2, pCAMBIA2300 or other suitable plant transformation vectors known in the art. In addition to the expression cassette, the plant transformation vector will contain such sequences as are necessary for the transformation process. These may include the Agrobacterium vir genes, one or more T-DNA border sequences, and a selectable marker or other means of identifying transgenic plant cells.

The term "expression vector or plant transformation vector" means a construct capable of in vivo or in vitro expression. Preferably, the expression vector is incorporated in the genome of the organism. In one embodiment the vector of the present invention expresses a protein e.g. an RNA binding protein as described herein. The term "incorporated" preferably covers stable incorporation into the genome.

Techniques for transforming plants are well known within the art and include Agrobacterium- mediated transformation, for example. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christon (AgroFood-lndustry Hi-Tech March/April 1994 17-27), which are incorporated herein by reference.

Typically, in Agrobacterium-mediated transformation a binary vector carrying a foreign DNA of interest, i.e. a construct according to the present invention, is transferred from an appropriate Agrobacterium strain to a target plant by the co-cultivation of the Agrobacterium with explants from the target plant. Transformed plant tissue is then regenerated on selection media, which selection media comprises a selectable marker and plant growth hormones. An alternative is the floral dip method (Clough & Bent, 1998 Plant J. 1998 Dec;16(6):735-43, which is incorporated herein by reference) whereby floral buds of an intact plant are brought into contact with a suspension of the Agrobacterium strain containing the chimeric gene, and following seed set, transformed individuals are germinated and identified by growth on selective media. Direct infection of plant tissues by Agrobacterium is a simple technique which has been widely employed and which is described in Butcher et al. (1980) Tissue Culture Methods for Plant Pathologists, eds.: D. S. Ingrams and J.P. Helgeson, 203-208 which is incorporated herein by reference.

Further suitable transformation methods include direct gene transfer into protoplasts using polyethylene glycol or electroporation techniques, particle bombardment, micro-injection and the use of silicon carbide fibres for example. Transforming plants using ballistic transformation and production of fertile transgenic maize plants by silicon carbide whisker-mediated transformation is taught in Frame et al. (1994) The Plant Journal 6(6): 941-948, which is incorporated herein by reference, and viral transformation techniques is taught in, for example, Meyer et al. (1992) Mol. Gen. Genet. 231 (3): 345-352, which is incorporated herein by reference. The use of cassava mosaic virus as a vector system for plants is taught in Meyer et al. (1992) Gene 110: 213-217, which is incorporated herein by reference. Further teachings on plant transformation may be found in EP-A-0449375, incorporated herein by reference.

In a further aspect, the present invention relates to a vector system which carries a construct and introducing it into the genome of an organism, such as a plant, suitably a tobacco plant. The vector system may comprise one vector, but it may comprise two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung et al. (1980) Binary Vectors, Plant Molecular Biology Manual A3, 1-19, which is incorporated herein by reference.

One extensively employed system for transformation of plant cells uses the Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes described by An et al. (1986) Plant Physiol. 81 , 301-305 and Butcher et al. (1980) Tissue Culture Methods for Plant Pathologists eds.: D. S. Ingrams and J.P. Helgeson, 203-208 which are incorporated herein by reference. After each introduction method of the desired exogenous gene according to the present invention in the plants, the presence and/or insertion of further DNA sequences may be necessary. The use of T-DNA for the transformation of plant cells has been intensively studied and is described in EP-A-120516; Hoekema (1985) The Binary Plant Vector System, Offset- drukkerij Kanters B. B., Amsterdam Chapter V; Fraley et al. Crit. Rev. Plant Sci. 4:1-46; and An et al. (1985) EMBO J 4: 277-284, all incorporated herein by reference.

Plant cells transformed with construct(s) which modulate the activity or expression of at least one gene encoding an RNA binding protein may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc. The term "transgenic plant" in relation to the present invention includes any plant that comprises a construct which modulates the activity or expression of at least one gene encoding an RNA binding protein according to the invention. Accordingly a transgenic plant is a plant which has been transformed with a construct according to the invention. Preferably the transgenic plant exhibits modulated (e.g. reduced) alkaloid content and/or modulated (e.g. reduced) TSNA precursor content according to the present invention. The term "transgenic plant" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

In one aspect, a gene encoding an RNA binding protein, a construct, a plant transformation vector or a plant cell according to the present invention is in an isolated form. The term "isolated" means that the sequence is at least substantially free from at least one other component with which the sequence is naturally associated in nature and as found in nature.

In one aspect, a gene encoding an RNA binding protein, a construct, plant transformation vector or a plant cell according to the invention is in a purified form. The term "purified" means in a relatively pure state, e.g. at least about 90% pure, or at least about 95% pure or at least about 98% pure.

The term “nucleotide sequence” as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or anti-sense strand.

The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention. In a preferred embodiment, the nucleotide sequence when relating to and when encompassed by the per se scope of the present invention, i.e. the gene encoding an RNA binding protein according to the present invention, includes the native nucleotide sequence when in its natural environment and when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the “native nucleotide sequence”. In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment.

The nucleotide sequence for use in the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host organism. The constructs for use in the present invention may be transformed into a suitable host cell as described herein to provide for expression of a polypeptide of the present invention. The choice of vector e.g. a plasmid, cosmid, or phage vector will often depend on the host cell into which it is to be introduced. Vectors may be used in vitro, for example for the production of RNA or used to transfect, transform, transduce or infect a host cell.

In some applications, the nucleotide sequence for use in the present invention is operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the nucleotide sequence of gene encoding an RNA binding protein as described herein operably linked to such a regulatory sequence, i.e. the vector is an expression vector.

The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

The term “regulatory sequences” includes promoters and enhancers and other expression regulation signals. The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site. The nucleotide sequence within a construct which encodes gene encoding an RNA binding protein may be operably linked to at least a promoter.

The term "construct" - which is synonymous with terms such as "cassette" or“vector” - includes a nucleotide sequence for use according to the present invention directly or indirectly attached to a promoter.

An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment. The construct may even contain or express a marker, which allows for the selection of the genetic construct.

In some embodiments, a promoter may be operably linked to nucleotide sequence in a construct or vector which is used to modulate the concentration and/or total content of nicotine in a cell or cell culture or tobacco plant or part thereof.

In some embodiments the promoter may be selected from the group consisting of: a constitutive promoter, a tissue-specific promoter, a developmentally-regulated promoter and an inducible promoter.

In one embodiment the promoter may be a constitutive promoter.

A constitutive promoter directs the expression of a gene throughout the various parts of a plant continuously during plant development, although the gene may not be expressed at the same level in all cell types. Examples of known constitutive promoters include those associated with the cauliflower mosaic virus 35S transcript (Odell JT, Nagy F, Chua NH. (1985). Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter. Nature. 313 810-2), the rice actin 1 gene (Zhang W, McElroy D, Wu R. (1991). Analysis of rice Act1 5' region activity in transgenic rice plants. Plant Cell 3 1155-65) and the maize ubiquitin 1 gene (Cornejo MJ, Luth D, Blankenship KM, Anderson OD, Blechl AE. (1993). Activity of a maize ubiquitin promoter in transgenic rice. Plant Molec. Biol. 23 567-81). Constitutive promoters such as the Carnation Etched Ring Virus (CERV) promoter (Hull R, Sadler J, LongstaffM (1986) (CaMV/35S), figwort mosaic virus 35S promoter. The sequence of carnation etched ring virus DNA: comparison with cauliflower mosaic virus and retroviruses. EMBO Journal, 5(2):3083- 3090).

The constitutive promoter may be selected from a: a carnation etched ring virus (CERV) promoter, a cauliflower mosaic virus (CaMV 35S promoter), a promoter from the rice actin 1 gene or the maize ubiquitin 1 gene.

The promoter may be a tissue specific promoter. A tissue-specific promoter is one which directs the expression of a gene in one (or a few) parts of a plant, usually throughout the lifetime of those plant parts. The category of tissue-specific promoter commonly also includes promoters whose specificity is not absolute, i.e. they may also direct expression at a lower level in tissues other than the preferred tissue. Tissue specific promoters include the phaseolin-promoter, legumin b4-promoter, usp-promoter, sbp-promoter, ST-LS1 promoter, B33 (patatin class I promoter). In another embodiment the promoter may be a developmentally-regulated promoter.

A developmentally-regulated promoter directs a change in the expression of a gene in one or more parts of a plant at a specific time during plant development. The gene may be expressed in that plant part at other times at a different (usually lower) level, and may also be expressed in other plant parts.

In one embodiment the promoter may be an inducible promoter.

An inducible promoter is capable of directing the expression of a gene in response to an inducer. In the absence of the inducer the gene will not be expressed. The inducer may act directly upon the promoter sequence, or may act by counteracting the effect of a repressor molecule. The inducer may be a chemical agent such as a metabolite, a protein, a growth regulator (such as auxin and salicylic acid which activate the OCS promoter), or a toxic element, a physiological stress such as heat, light (such as the soybean SSU promoter), wounding (e.g. the nos, nopaline synthase promoter), or osmotic pressure, or an indirect consequence of the action of a pathogen or pest. A developmentally-regulated promoter might be described as a specific type of inducible promoter responding to an endogenous inducer produced by the plant or to an environmental stimulus at a particular point in the life cycle of the plant. Examples of known inducible promoters include those associated with wound response, such as described by Warner SA, Scott R, Draper J. ((1993) Plant J. 3 191-201), temperature response as disclosed by Benfey & Chua (1989) (Benfey, P.N., and Chua, N-H. ((1989) Science 244 174- 181), and chemically induced, as described by Gatz ((1995) Methods in Cell Biol. 50 411-424).

A nucleotide sequence encoding either a protein which has the specific properties as gene encoding an RNA binding protein as defined herein or a protein which is suitable for modification may be identified and/or isolated and/or purified from any cell or organism producing said protein. Various methods are well known within the art for the identification and/or isolation and/or purification of nucleotide sequences. By way of example, PCR amplification techniques to prepare more of a sequence may be used once a suitable sequence has been identified and/or isolated and/or purified.

In a yet further alternative, the nucleotide sequence encoding the RNA binding protein may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage et al. (1981) Tetrahedron Letters 22, 1859-1869 which is incorporated herein by reference, or the method described by Matthes et al. (1984) EMBO J. 3, 801-805 which is incorporated herein by reference. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

As used herein, the term“amino acid sequence” is synonymous with the term“polypeptide” and/or the term“protein”. In some instances, the term“amino acid sequence” is synonymous with the term“peptide”. In some instances, the term“amino acid sequence” is synonymous with the term“enzyme”.

The present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence i.e. a gene encoding an RNA binding protein (hereinafter referred to as a“homologous sequence(s)”). Here, the term“homologue” means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term“homology” can be equated with“identity”.

The homologous amino acid sequence and/or nucleotide sequence and/or fragments should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the RNA binding protein. Typically, the homologous sequences will comprise the same active sites etc. as the subject amino acid sequence for instance or will encode the same active sites. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. Homologous sequences typically retain functional domains or motifs.

In one embodiment, a homologous sequence is taken to include an amino acid sequence or nucleotide sequence which has one, two or several additions, deletions and/or substitutions compared with the subject sequence.

Sequence identity

Sequence identity comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. % homology or % identity may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting“gaps” in the sequence alignment to try to maximise local homology. However, these more complex methods assign“gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the Vector NTI (Invitrogen Corp.). Examples of software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al. (1999) Short Protocols in Molecular Biology, 4th Ed - Chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov), FASTA (Altschul et al. 1990 J. Mol. Biol. 403-410) and AlignX for example. At least BLAST, BLAST 2 and FASTA are available for offline and online searching (see Ausubel et al. 1999, pages 7-58 to 7-60).

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI package.

Alternatively, percentage homologies may be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244). Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

Should gap penalties be used when determining sequence identity, then preferably the following parameters are used for pairwise alignment:

In one embodiment, CLUSTAL may be used with the gap penalty and gap extension set as defined above. In some embodiments the gap penalties used for BLAST or CLUSTAL alignment may be different to those detailed above. The skilled person will appreciate that the standard parameters for performing BLAST and CLUSTAL alignments may change periodically and will be able to select appropriate parameters based on the standard parameters detailed for BLAST or CLUSTAL alignment algorithms at the time.

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 70 contiguous nucleotides, preferably over at least 80 contiguous nucleotides, preferably over at least 90 contiguous nucleotides, preferably over at least 100 contiguous nucleotides, preferably over at least 150 contiguous nucleotides, preferably over at least 200 contiguous nucleotides, preferably over at least 250 contiguous nucleotides, preferably over at least 300 contiguous nucleotides, preferably over at least 350 contiguous nucleotides, preferably over at least 400 contiguous nucleotides, preferably over at least 450 contiguous nucleotides, preferably over at least 500 contiguous nucleotides, preferably over at least 550 contiguous nucleotides, preferably over at least 600 contiguous nucleotides, preferably over at least 650 contiguous nucleotides, or preferably over at least 700 contiguous nucleotides.

Suitably, the degree of identity with regard to a nucleotide, cDNA, cds or amino acid sequence may be determined over the whole sequence.

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

Replacements may also be made by unnatural amino acids include; alpha* and alpha- disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids such as trifluorotyrosine*, p-CI-phenylalanine*, p-Br-phenylalanine*, p-l-phenylalanine*, L- allyl-glycine*, b-alanine*, L-a-amino butyric acid*, L-y-amino butyric acid*, L-a-amino isobutyric acid*, L-s-amino caproic acid ^# , 7-amino heptanoic acid*, L-methionine sulfone ^#* , L-norleucine*, L-norvaline*, p-nitro-L-phenylalanine*, L-hydroxyproline ^# , L-thioproline*, methyl derivatives of phenylalanine (Phe) such as 4-methyl-Phe*, pentamethyl-Phe*, L-Phe (4-amino) ^# , L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (1 ,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)*, L- diaminopropionic acid ^# and L-Phe (4-benzyl)*. The notation * has been utilised for the purpose of the discussion above (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #* indicates amphipathic characteristics.

Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or b-alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, which will be well understood by those skilled in the art. For the avoidance of doubt,“the peptoid form” is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue’s nitrogen atom rather than the a-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon et al. (1992) PNAS 89(20), 9367-9371 and Horwell (1995) Trends Biotechnol. 13(4), 132-134. The nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences of the present invention.

The present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto. The term “hybridisation” as used herein shall include“the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.

The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein). Preferably, hybridisation is determined under stringency conditions (e.g. 50°C and 0.2xSSC {1xSSC = 0.15 M NaCI, 0.015 M Na ₃ citrate pH 7.0}). More preferably, hybridisation is determined under high stringency conditions (e.g. 65°C and O.lxSSC {1xSSC = 0.15 M NaCI, 0.015 M Nascitrate pH 7.0}).

A review of the general techniques used for transforming plants may be found in articles such as Potrykus et al. (1991) Annu Rev Plant Physiol. Plant Mol. Biol. 42:205-225 and Christou et al. (1994) Agro-Food-Industry Hi-Tech March/April 17-27, which are incorporated herein by reference. Further teachings on plant transformation may be found in EP-A-0449375, incorporated herein by reference.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide one of skill with a general dictionary of many of the terms used in this disclosure.

This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation. The term “protein", as used herein, includes proteins, polypeptides, and peptides. As used herein, the term “amino acid sequence” is synonymous with the term“polypeptide” and/or the term“protein”. In some instances, the term “amino acid sequence” is synonymous with the term“peptide”. In some instances, the term “amino acid sequence” is synonymous with the term“enzyme”.

In the present disclosure and claims, the conventional one-letter and three-letter codes for amino acid residues may be used. The 3-letter code for amino acids as defined in conformity with the lUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.

Other definitions of terms may appear throughout the specification. Before the exemplary embodiments are described in more detail, it is to understand that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an enzyme" or “a nitrate reductase” includes a plurality of such candidate agents and equivalents thereof known to those skilled in the art, and so forth.

Advantages

It has been surprisingly found that by modulating the activity or expression of at least one gene encoding an RNA binding protein as taught herein which acts as a positive regulator of alkaloid content in tobacco, the alkaloid and/or TSNA precursor content of plants can be modulated. Thereby tobacco industry products with modulated (e.g. reduced) alkaloid content) and/or reduced TSNA precursor content and commercially desirable traits sought after by consumers of tobacco industry products can be produced.

The present inventors have surprisingly determined a method for modulating the alkaloid content and/or TSNA precursor content of a plant (e.g. tobacco plant) by modulating the activity or expression of a gene encoding an RNA binding protein. Alkaloid or TSNA precursor content of a plant (e.g. tobacco plant) may be decreased by decreasing or inhibiting the activity or expression of a gene encoding an RNA binding protein as described herein. Prior to the present invention it had not been known that modulation of the activity or expression of a gene encoding an RNA binding protein as described herein could be used to modulate alkaloid (and/or TSNA precursor content of a plant (e.g. a tobacco plant).

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto.

EXAMPLES

Example 1 - Transient overexpression of gene encoding an RNA binding protein increases alkaloid content in leaves

Methods and Materials

Cloning an RNA binding protein expression vector

The Nitab4.5_0013685g0010.2 gene sequence (SEQ ID NO. 3) encoding an RNA binding protein according to the invention was amplified from a Gateway™ compatible cDNA library using primers located outside restriction sites flanking the gene sequence.

The resulting plasmid was sequenced and transformed into Agrobacterium tumefaciens GV3101 pMP90 by heat shock and transiently expressed in tobacco leaves.

Transient gene expression

Agrobacterium tumefaciens GV3101 strains carrying the construct of interest were grown overnight in Luria-Bertani (LB) medium supplemented with appropriate antibiotics. Cultures were spun down and re-suspended in buffer containing 10 mM MgC , 10 mM MES pH 5.6 and 100 mM acetosyringone to OD600=0.6 and incubated for one hour at room temperature. Infiltration was performed with a needleless syringe into tobacco leaves. Samples are taken 5 days post-infiltration.

Tests were performed in two biological replicates.

Alkaloid measurement

Relative content of pyridine alkaloids was determined by reversed phase high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS). Chromatographic separation was achieved using a Gemini-NX column (100 mm ^c 3.0 mm, particle size 3 pm, Phenomenex) and gradient chromatographic separation using 6.5 mM ammonium acetate buffer (aq) (pH 10) and Methanol.

Mass Spectrometer operates in electrospray (ESI) positive mode using scheduled MRM data acquisition. Two MRM transitions were monitored for each analyte and one for the isotope labelled internal standard.

Results

Alkaloid content of 5-week-old tobacco leaves expressing the Nitab4.5_0013685g0010.2 construct is shown in Figure 1. Alkaloid content is represented relative to control and comprises two biological replicates analysed by one-way t-test. Values are shown as means ± SEM. Asterisks indicate statistical significance of P value £ 0.01.

Overexpression of Nitab4.5_0013685g0010.2 leads to a significant increase in alkaloid content in leaves.

Conclusions

Nitab4.5_0013685g0010.2 is a positive regulator of alkaloid content, and is a regulator of pyridine alkaloids in tobacco.

Example 2 - Transient expression of antisense RNA targeting Nitab4.5 0013685g0010.2 decreases alkaloid content in leaves

Materials and Methods

The Nitab4.5_0013685g0010.2 coding sequence was cloned in reverse orientation into a plant expression vector driven by the CERV promoter.

Results

Alkaloid content of 5-week-old tobacco leaves expressing Nitab4.5_0013685g0010.2antisense RNA is shown in Figure 2. Alkaloid content is represented relative to control and comprises two biological replicates analysed by t-test. Values are shown as means ± SEM. Asterisks indicate statistical significance of P value £ 0.01

Suppressing Nitab4.5_0013685g0010.2 expression using antisense RNA leads to a decrease in alkaloid content in leaves, in particular a decrease in nornicotine, PON, nicotine, anabasine and anatabine content. Conclusions

Nitab4.5_0013685g0010.2 is a positive regulator of alkaloid content, in particular alkaloid content in leaves and is a regulator of pyridine alkaloids in tobacco.

Example 3 - Transient expression of Nitab4.5 0013685q0010.2 deltaRBD-RGG leads to a siqnificant reduction in alkaloids.

Materials and Methods

The Nitab4.5_0013685g0010.2_deltaRBD-RGG coding sequence (SEQ ID NO: 34) was cloned into an expression vector as described in Example 1.

Results

Alkaloid content of 5-week-old tobacco leaves expressing Nitab4.5_0013685g0010.2_deltaRBD-RGG is shown in Figure 3. Alkaloid content is represented relative to control and comprises two biological replicates analysed by t- test. Values are shown as means ± SEM. Asterisks indicate statistical significance of P value < 0.05.

Conclusions

Disruption of the RBD-RGG domain in RNA binding proteins modulates alkaloid content in tobacco leaves.

Example 4 - Homoloque testing

The effects of the homologues of SEQ ID NO. 3, namely SEQ ID NOs 6, 9, 12, 15, 18, 21 , 24,

27 and 30, are tested in assays as described in the above examples.

Example 5 - Interactome study of Nitab4.5 0013685g0010.2

Method:

Triplicate co-immunoprecipitation samples of Nitab4.5_0013685g0010.2 were submitted to mass spectrometry analysis. Samples were digested with trypsin and analysed on a Thermo Scientific™ Orbitrap Fusion™ mass spectrometer. Data was analysed with Proteome Discoverer 2.1 against the BAT tobacco proteome database and common contaminant databases, using a 5% false discovery rate. Proteins were sorted based on: identification in all replicates of the candidate sample; the number of peptides identified, in the candidate sample; and not present in control (GFP) or the other candidate samples. Using these criteria a list of candidate interactors for Nitab4.5_0013685g0010.2 was generated. Results and Conclusion:

Mass spectrometry analysis of the triplicate samples identified the bait protein correctly in each sample. In addition, other proteins were also identified in each sample which enable the characterisation of Nitab4.5_0013685g0010.2 proteome (data not shown). Several interactors are RNA binding proteins. This class of glycine-rich RNA binding proteins are known to bind RNA and interact with other proteins involved in RNA processing.